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Acute Lymphoblastic Leukemia (ALL) is an aggressive hematologic tumor 
and is the most common malignancy in children (Horton and Steuber 2014). This 
disease is characterized by the infiltration of bone marrow by malignant immature 
lymphoid progenitor cells and is invariably fatal without treatment.  Although 
multi-agent combination chemotherapy is curative in a significant fraction of ALL 
patients, treatment currently fails in approximately 20% of children and up to 50% 
of adults with ALL, making relapse and drug resistance the most substantial 
challenge in the treatment of this disease(Fielding, Richards et al. 2007, Aster 
and DeAngelo 2013). Understanding what causes treatment failure is of great 
medical importance as second line therapies also fail in the majority of relapse T-
cell ALL (TALL)  patients (Fielding, Richards et al. 2007, Aster and DeAngelo 
2013). Using next-generation sequencing to compare the genomes of tumors 
before and after therapy, mutations in gene cytosolic 5’-nucleotidase II (NT5C2) 
were discovered in 19% of pediatric samples with relapsed T-ALL(Tzoneva, 
Carpenter et al. 2013). Preliminary structure function analysis and subsequent in 
vitro experimental nucleotidase activity assays confirmed that these mutations 


lead to hyperactive NT5C2 protein. Furthermore, NT5C2 mutant proteins 
conferred resistance to 6-mercaptopurine and 6-thioguanine chemotherapy drugs 
when expressed in ALL lymphoblasts, suggesting NT5C2 is responsible for the 
inactivation of nucleoside-analog chemotherapy drugs. In order to assess the 
ability of these mutations to lead to novel inhibitor schemes, the functional impact 
of each mutation was analyzed through robust structure function methods. The 
result of this in silico analysis, is the identification of a potential allosteric 
regulatory mechanism of negative feedback inhibition never before described. 
Most notably, the majority of NT5C2 mutations identified have characteristics that 
suggest they abrogate the function of this proposed mechanism, yielding a novel 
viable target for the development of allosteric inhibitors specific for constitutively 
active NT5C2 mutant proteins. Overall these findings support a prominent role 
for activating mutations in NT5C2 and chemotherapy resistance in ALL, 
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Chapter 1. Introduction 
 
1.A. Next Generation DNA Sequencing and Future Perspectives in Oncology 
Sequencing technology has made incredible strides in efficiency and accuracy since the 
inception of Sanger’s landmark discoveries in 1977(Sanger, Nicklen et al. 1977). The future 
will witness widespread adoption of next generation sequencing (NGS) in clinical diagnostics, 
translational research, and basic science. Today’s leading NGS platforms offer high-quality 
rapid turnover of DNA samples at costs approaching $1,000 per genome - a precipitous drop 
from the 2.7 billion dollar human genome project which concluded just over a decade ago in 
2001. Oncology is one area of application with a particularly bright future, and in the past 
decade NGS technologies have already facilitated a dramatic shift in our view of cancer as a 
disease(Kulkarni and Ma 2013). While it is now well established that cancer is a genomic 
disease, sequencing has enabled researchers for the first time to appreciate just how 
dramatically different cancers can be on a molecular level. In the context of other genetic 
alterations such as amplifications, deletions, gene fusions, and epigenetic changes, the 
combined altered-genomics picture of any given tumor type becomes widely complex. 
Furthermore, while the notion of inter-tumor heterogeneity has become an accepted concept, 
our understanding of intra-tumor heterogeneity remains limited(Kulkarni and Ma 2013).  
It is estimated that NGS adoption in oncology will approach penetration of 25 to 70 
percent of presenting adjuvant and metastatic patients within 5 years(Kulkarni and Ma 2013). 
As there are limited pharmacological interventions available to physicians, not every indication 
will benefit from the increased information obtained through NGS. From a clinical perspective, 
therefore, the most attractive target candidates are those with a prominent role in driving 


disease. While the number and variety of genetic variations across a given cohort of patients 
can be staggering, prevailing notion maintains that the vast majority are ‘passenger’, or 
secondary, in nature and only a small subset are responsible for driving disease. Identification 
of these alterations, called ‘drivers’, is held as the key to unlocking new therapeutic and 
diagnostic avenues. Thus, the major hurdle limiting the extent of NGS’s impact in clinical 
diagnostics and translational medicine is not physical limitations or cost, but, rather, the 
actionability of the sequence information that is generated.  The paramount questions, 
therefore, become: in a world of increasingly large datasets, what is the optimal method to 
prioritize genetic alterations that deserve additional investigation? Which alterations are those 
that hold the greatest potential translationally?  
 
In this thesis, I will explain how post-processing information, with a heightened 
focus on protein structure analysis, can greatly increase the actionability of next 
generation sequencing results. In particular, I will focus on my work to elucidate the 
genetic causes of drug resistance derived relapse in T-cell Acute lymphoblastic 
Leukemia (T-ALL). Although T-ALL was one of the first human cancers to be treated 
successfully with chemotherapy, treatment currently fails in approximately 20% of 
children and up to 50% of adults with ALL(Fielding, Richards et al. 2007, Aster and 
DeAngelo 2013). Understanding what causes this treatment failure is of great medical 
importance as second line therapies also fail in the majority of relapse T-ALL 
patients(Fielding, Richards et al. 2007, Aster and DeAngelo 2013). Using next-
generation sequencing to compare the genomes of tumors before and after therapy, I 
uncovered a likely mechanism of therapy resistance in T-ALL. This approach identified 


a single mutation in enzyme cytosolic 5’-nucleotidase II (NT5C2) in one out of five 
pediatric samples with relapsed T-ALL, at which point the task of understanding how it 
might impact protein function to lead to drug resistance came to light. Through structure 
function analysis of this sentinel case, I ascertained the activating role of NT5C2 
mutation K359Q, suggesting that it may directly drive drug resistance in relapsed T-ALL 
patients.  To investigate the recurrence of this mutation, targeted sequencing was 
subsequently performed for 103 total patients with relapsed T-ALL, revealing 20 
validated NT5C2 mutations. These findings suggested that NT5C2 may play a role in 
drug resistance of close to one fifth (19%) of all T-ALL relapse patients(Tzoneva, 
Carpenter et al. 2013). The identification of a novel allosteric inhibitory mechanism 
documented in this thesis, opens the door to the development of a new class of toxicity-
free inhibitors targeting constitutively active mutant forms of NT5C2. As NT5C2 
overexpression has been associated with acute myeloid leukemia, chronic lymphoid 
leukemia, various lung cancers, high-risk myelodysplatic syndrome, hairy cell leukemia, 
and colorectal carcinoma, in addition to T- and B-ALL, a NT5C2 specific inhibitor holds 
the potential to help many cancer patients in the future (Tibaldi, Giovannetti et al. 2008, 
Yamauchi, Negoro et al. 2009, Mitra, Crews et al. 2011, Cancer Genome Atlas 2012, 
Petter Jordheim and Chaloin 2013).  
The structure of this thesis will reflect the scientific logic that led to the 
identification and prioritization of genetic aberrations responsible for drug resistance.  
This first chapter will provide a general introduction to the next generation sequencing 
workflow I have utilized, with a particular focus on methods used to prioritize specific 
genetic alterations for further study. In chapter 2, I will illustrate the application of this 
	

workflow through our analysis of T-ALL sequencing results, documenting the 
collaborative discovery and prioritization of novel alterations associated with relapse. In 
the final chapter, I will focus on the most promising identified candidate, NT5C2, utilizing 
a dataset created across several publications to build a unifying model for mutation 
based hyperactivity of NT5C2 in T-ALL relapse patients.  
  
1.A.i Next Generation DNA Sequencing workflows 
From wet-lab to dry-lab, next generation workflows involve many steps including: 
sample preparation, detection, statistical analysis, validation, and frequency/recurrence 
analysis. Sample preparation begins with use of a template library selected from genomic, 
cDNA, PCR, or other sources. Template DNA taken from one of these sources is lysed into 
smaller segments through mechanical shearing, and then annealed to adaptors specific to 
various sequencing platforms. The resultant template library can then be further enriched 
along particular regions of interest. One method of achieving this enrichment is through 
hybridization to a selective microarray, allowing selected regions of the template library to be 
kept, and the rest washed away in elution steps. Biotinalated RNA “bait” libraries that are 
homologous to genomic regions of interest offer an additional method of template library 
enrichment. For a more detailed view of sequencing preparation please see review (Sulonen et 
al., 2011)(Sulonen, Ellonen et al. 2011). 
Two key parameters that affect the quality of NGS data are DNA library size 
distribution and DNA library concentration.  Each sequencing platform will generate 
different size read lengths, and therefore if the size of the DNA library is much larger 




may be unable to assemble into contiguous reads. Accurate quantification of genomic 
template is also critical because all major sequencing technologies rely on specific 
target densities during template immobilization.  
The detection, or sequencing, step can be accomplished through several major 
technologies developed at Illumina, Pacific Biosystems, Roche and other companies. These 
platforms differ in sequencing chemistry, read length, run time, and the amount of DNA that 
can be sequenced per run, but all rely on clonal amplification of the input template DNA or 
RNA materials. The Illumina platform, utilized in all experiment designs in this thesis, uses an 
immobilized DNA strand as a template for reading sequences as nucleotides added to a 
growing strand (Figure 1.1). For a detailed review on sequencing chemistry and products 




1.A.ii Cancer Gene Identification and Quality Control 
Following the chemical reactions of NGS sequencing, regardless of platform choice, a 
cumbersome set of data is created in the raw format of sequencing read files. These files are 
very large and require significant processing before they can be interpreted biologically. The 
first step of processing involves hierarchical organization of the data by sample type and ID 
onto local storage and computing clusters. On these clusters the samples are mapped to a 
reference genome enabling the acquired reads to be aligned and annotated with respect a 
matched position within a particular organisms genome.  The reference genome utilized in 


these sequencing projects (except where otherwise specified) is hg19, which is provided and 
maintained by the UCSC Genome browser(Karolchik, Baertsch et al. 2003). After matched 
normal and tumor pairs (or triplets in which case a third sample would be matched) from a 
patient under go this process, it is then possible to compare particular genetic loci before and 
after transformation. Due to errors intrinsic to sequencing instrumentation, however, the 
comparative picture at this stage remains heavily convoluted; artifacts introduced through bias 
or error can often appear indistinguishable from authentic genetic lesions(Trifonov, 
Pasqualucci et al. 2013).  
The correction of noise introduced by error and bias, therefore, represents an important 
and logical step towards meaningful comparative analysis of related samples. Traditionally, 
statistical approaches designed to address platform-derived errors have concentrated on 
furnishing a binary call regarding any particular mutations presence or absence. These 
methods establish a call for each variant through utilization of arbitrary thresholds relating to 
the number of reads reporting a variant, their quality, and the total number of reads covering 
the variant’s position (Trifonov et al., 2010;(Li, Wang et al. 2011);(Morin, Johnson et al. 2010)). 
As the depths along the genome are unevenly distributed, these arbitrary thresholds act to 
introduce significant bias, and will screen variants that feature high depth and low quality, or 
the reciprocal situation of low depth and high quality. Discretization of the data in this manner 
leads to problems in instances with heterogeneous samples (ie contamination or other quality 
issues) [Trifonov et al., 2010; Li et al., 2011]. Additionally, as low frequency alleles can have 
marked impact on disease in later stages, a digital call of this type, does not take advantage of 
all available data, specifically in that it fails to consider differences in frequency of alleles 
(Trifonov et al., 2010;(Fabbri, Rasi et al. 2011)). Knowledge of frequencies holds the potential 


to critically impact prognostic precision, particularly when samples along multiple time points 
are available (such as biopsy, surgery, and relapse samples all of an individual 
patient)(Trifonov et al., 2010). In the goal of establishing a statistical approach applicable in 
diverse scenarios that rationally addresses bias and systematic errors, and fully utilizes 
available allele frequency information, the Rabadan Lab developed the Statistical Algorithm for 
Variant Frequency Identification (SAVI) in the course of the comparative analysis of Hairy Cell 
Leukemia (HCL) patients (Tiacci et al., 2011)(Figure 1.2). Fundamentally, SAVI constructs 
Bayesian posterior distributions of allele frequencies, utilizing an iterative procedure with a 
fixed-point distribution for construction of an empirical prior from a given dataset. These 
posterior distributions allow high credibility interval for the frequency of particular alleles, in 
addition to presenting expected and most likely values (Trifonov et al., 2010). These 
distribution derived high credibility intervals are then used to decide between competing variant 
present/absent hypotheses, and to distinguish authentic alleles from those introduced as 
artifacts by sequencing instrumentation (Trifonov et al., 2010). Utilizing the SAVI algorithm for 
variant calling has enabled the sequencing conducted in this thesis to be more reliable than 
that allowed by other contemporary methods, and thus is a critical component in many aspects 
of these works. The general mechanics of SAVI workflow, which have been designed to 
include mapping and quality control steps aforementioned, are outlined in Figure 1.2 (Trifonov 




1.A.iii Cancer Gene Prioritization 
While the number and variety of DNA variations across a given cohort of patients 
can be staggering, the prevailing notion maintains that the vast majority of alterations 
within tumor genomes are passenger or secondary in nature and only a small subset 
are responsible for driving disease. This nature of tumors is demonstrated by many 
analyses; for example, only eight genes from an original pool of 453 validated non-silent 
mutations across 223 distinct genes in glioblastoma multiform (GBM) provided evidence 
of positive selection pressure (Sjöblom, Jones et al. 2006, Greenman, Stephens et al. 


2007, Chin, Hahn et al. 2011).  
While mutation calling by the SAVI pipeline allows for statistical detection of 
mutations with unprecedented accuracy, it provides insufficient information for optimal 
prioritization of variants for research. In light of rapidly improving sequencing 
technologies and increasingly large datasets, prioritization of validated non-silent 
mutations represents an increasingly integral step in NGS analysis of cancer 




Through use of computational and theoretical analysis, the number potential driver 
mutations present in the initial pool of validations can be greatly reduced, with false 
negative rates at low levels. The benefit of such pursuits is manifold, as the majority of 
called mutations are likely to represent passenger events and confer little to no growth 
advantages in tumors (The Cancer Genome Atlas Network 2008; Chin et al, 2011; 
Greenman et al., 2007; Sjoblom et al. 2006).  
1.A.iii.a Database Annotation Overlay and Synthesis 
 
Various databases exist towards the goalof categorizing sectors, domains, 
motifs, and functional sites in proteins. Phosphorylationsites, ubiquitinylation sites, 
glycosylation sites, signal peptide motifs, metal binding sites, localization signals, 
and cleavage sitesrepresent a very small example set of annotatedsequence 
information that can add great benefitto mutational analysis(Gasteiger, Gattiker et al. 
2003). To be able to screen data of this sort one can build curl text mining algorithms or 
even simply browse and download (as many sites now offer this feature) to establish 
local databases that can be queried through use of basic text parsing and regular 
expressions to quickly identify functional sites or domains of importance overlapping 
with mutations identified through NGS experiments. Additionally, when these 
annotations are lacking, which is common amongst lesser-studied proteins, many tools 
exist to predict functional sites and motifs. The most comprehensive assembly of such 
resources can be found at the ExPasy Proteomics Tools Portal(Artimo, Jonnalagedda et 
al. 2012).  


Particularly important resources to tumor mutation prioritization are databases 
like COSMIC and the Cancer Gene Census 
(http://www.sanger.ac.uk/genetics/CGP/Census/), which provide documentation of 
cancer related mutations. Acknowledging these mutations is of critical importance, as 
the overlap between different cancers in regard to transformation is both intuitive and 
substantially demonstrated (Forbes, Bhamra et al. 2008, Forbes, Tang et al. 2009, 
Forbes, Bindal et al. 2010),(Alkan, Coe et al. 2011, Alkan, Sajjadian et al. 2011). Very 
few of the available prediction programs or database annotations are integrated into 
high-throughput mutation impact algorithms and thus, these methods represent 
important value added steps to interpretation of sequencing output. 
 
Outside of information regarding specific genes, mutations can also be 
interpreted through analysis of the signaling pathways in which they occur. Databases 
that categorize protein-protein interaction pathways provide a valuable resource that 
can serve to identify unseen patterns in NGS data. Pathway analysis is especially useful 
when multiple samples are available, as meaningful mutations can occur in a mutually 
exclusive manner with respect to specific pathways (Parsons, Jones et al. 2008, Lee, 
Yue et al. 2009). This concept is particularly relevant to understanding drug escape 
mechanisms in patients exhibiting chemotherapy resistance and relapse of disease as 
genes can share metabolic pathways in common with drug metabolism.  
 
1.A.iii.b Primary Sequence Methods 
At the most fundamental level, variant amino acids fall into various categories 


based on physio-chemical characteristics such as hydrophobicity, charge density, and 
polarity. These chemical identities, and their intrinsic propensity to determine secondary 
and tertiary structure in proteins, provide the foundation for interpretation of amino acid 
substitutions. Most amino acid substitution (AAS) predictive methods utilize an empirical 
severity index to score an amino acid change on a very fundamental level(Ng and 
Henikoff 2006). Many such indexes have been borrowed from substitution matrices 
created for use in alignment algorithms, in which particular amino acid substitutions are 
assigned a respective “penalty”(in certain blast algorithms, for example), and are in 
some way incorporated in all AAS methods. One of the most informative tools available 
for assessing the importance of mutation is the multiple sequence alignment (MSA), 
which allows for analysis of the conservation of its respective wild type allele. This 
conservation can be considered in either terms of absolute amino acid change, or in 
terms of class changes, such as hydrophobic to polar and etc. Most algorithms based 
on sequence information employ MSA of homologous proteins to provide a context in 
which to interpret the conservation of a particular site. Specifically, a multiple sequence 
alignment comprising a sufficient range of orthologous sequences reveals how far in 
evolutionary time particular sites are conserved. By analyzing the genetic distance 
between the organism containing the first protein to harbor a divergent amino acid and 
the query organism (in this case human), one can create quantifiable predictions on 
importance through naïve Bayes Classifiers (Adzhubei, Schmidt et al. 2010, Reva, 
Antipin et al. 2011). Reciprocally, ambiguity witnessed at a particular site in closely 
related species is a very good indication of neutral or benign effects (Ng et al, 2006; 
Adzhubei et al, 2010). These primary structural changes often translate into alterations 
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in secondary and tertiary structure that can drastically alter protein function stability. 
Predicting the impact of such structural changes can yield valuable insight into a 
mutation’s role in disease.  
1.A.iii.c Structural Methods 
Changes in secondary structure can be predicted through use of ab initio and 
conservation based algorithms at increasing accuracy. Many methods exist to assess 
the secondary structure impact of a particular mutation on protein function (Table 1.2) 
(Rost, Yachdav et al. 2004).  This analysis is particularly relevant when mutations occur 
in protein domains with well studied secondary structures. For example, the break of an 
amphipathic helix within a membrane-spanning region may alter a proteins stability 
leading to altered localization or singling properties.   
The most powerful and comprehensive form of computational functional impact 
depends on a high quality crystal structure or model featuring regions containing the 
somatic mutations of interest. Tertiary structural predictions, strive to analyze how a 
mutation impactsthe global conformation and stability of aprotein region, but 
explicitly require a solved structureor high quality model to be feasible. Givensuch a 
model, factors such as solventaccessibility, cavity volume and shape, carbon-beta 
density, crystallographic B-factor, freeenergy, torsional clashing, ionic interactions, 
covalent interactions (such as cofactorassociation or disulfide bonding), 
hydrogenbonding, and many others can be comparatively analyzedbetween mutant 
and wild-type (Petterson et al.,2004). Techniques that utilize crystal structures can be 
divided roughly into two types: high-throughput and manual. High throughput methods 




and provide output calls on each mutation. These methods vary widely in their 
approaches but most, if not all, utilize homology-based template matching to existing 
protein crystal structures. While extremely labor efficient, these techniques come along 
with pitfalls as well. Annotations based solely on structural similarity can at times cloud 
the picture of a mutations role through introduction of incorrect assumptions caused by 
high structural similarity but lack of true relevance to a mutation. This type of issues can 
be seen in protein families with highly conserved structural folds concurrent with areas 
of high variability(Scheeff and Bourne 2005).  Mutations occurring in substrate 
specificity residues, for-example can be incorrectly interpreted as benign due to the 
variability seen across structures at these sites. Furthermore, structures are often 
manipulated to increase their stability or achieve other desired effects during 
crystallization protocols. This is often necessary in highly flexible proteins and 
membrane spanning proteins, for example. In the event of a mutation occurring in one 
of these proteins, non-physiologic structures can inadvertently lead to incorrect 
conclusions. As end output of many high-throughput servers is often statistical scores or 
binary calls on impact, the user is unaware of such problems, particularly when dealing 
with large datasets.  
Although increase in computer processing speed and big data utilization is 
rapidly improving the ability of high throughput algorithms to predict meaningful 
mutations, ultimately, functional impact is best assessed manually. Methods that enable 
this investigation form the second loose grouping of crystal structure dependent 
mutation impact assessing techniques. Through more advanced structural manipulation 
tools, biophysics, and visualization software these techniques give researchers a 
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cockpit-eye view to analyze mutations on a case-by-case basis. This focused approach 
enables researchers to go beyond binary calls based on arbitrary statistics, and ask 
experimentally relevant questions whose solutions enable legitimate biological findings 
in the context of disease. As computational speed increases, the line between these two 
sets of tools becomes more and more blurred. Two examples are SWISS-MODEL and 
I-TASSER (Figure 1.3) which operate as servers for modeling and functional predictions 
of proteins in a format accessible to researchers of all backgrounds(Guex and Peitsch 
1997, Roy, Kucukural et al. 2010). By restricting user input into very specific inputs 
these tools are able to utilize complex algorithms remotely and provide the user with 
much more comprehensive results then that of algorithms like Poly-Phen2. The 
sacrifice, of course, is throughput; I-TASSER for example requires roughly 2 or more 
days to accomplish structural refinement assembly simulations on a single protein 
prediction(Roy, Kucukural et al. 2010). The optimal solution put forth by researchers 
faced by daunting sets of data, therefore, is employment of high throughput techniques 
and available database annotations as a cursory prioritization for candidates worthy of 




  While sequencing becomes more powerful and accessible, the genomes of 
tumors remain highly complex. As NGS becomes a reality in clinics and medical 
paradigm shifts towards a more personalized approach, a significant challenge facing 
both academic researchers and pharmaceutical companies alike lies in first, 
identification of driver mutations from passenger background, and second, 
understanding the impact of these alterations to an extent that enables the rationale 
development of targeted therapeutics. Post processing techniques that can prioritize 
genetic perturbations with regard to disease are thus of great value. In this thesis, the 
NGS technologies and prioritization techniques described above were applied towards 


furthering medical understanding of T-ALL both at diagnosis and in drug resistant 
disease relapse.  
 
Chapter 2. Unraveling the Mutation Landscape of relapse in 
T-cell Acute Lymphoblastic Leukemia  
2.A Introduction 
2.A.i Clinical Status of T-ALL 
 T-cell acute lymphoblastic 
leukemia (T-ALL) is an aggressive 
hematologic malignancy that develops 
primarily in pediatric and adolescent 
patients. Patients with this disease 
routinely feature high peripheral-blood-
cell counts, increased numbers of blast 
cells, CNS dissemination, large 
mediastinal masses (Horton and 
Steuber 2014)(Figure 1.B.1) While T-
ALL often arises in the thymus, it 
displays considerable propensity for 
invasion into bone marrow and 
peripheral tissue and is invariably fatal 

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without treatment (Horton and Steuber 2014). In the past 50 years, prognosis for 
pediatric T-ALL patients has improved remarkably from an initial median survival of 2 
months to overall survival rates of over 80%(Pui, Relling et al. 2004, Grabher and 
Harald von Boehmer 2006). Survival in treatment of adult patients has seen less 
significant improvement, with overall survival remaining around 50% in patients under 
60, and 20%-30% in those over age 60(Grabher and Harald von Boehmer 2006, 
Fielding, Richards et al. 2007) The best hope for continued progress in disease 
treatment lies in a better understanding of TALL pathobiology and in the driving 
mechanisms that lead to chemotherapy resistance.  
2.A.ii Underlying Genomic Mechanisms  
T-cell acute lymphoblastic leukemia arises through malignant transformation of 
T-cell progenitors in which normal thymocyte development undergoes a shift to an 
aberrant state of cellular growth, proliferation, survival, and differentiation. Analysis of 
these changes on molecular and genetic levels has contributed greatly to our 
understanding of the pathology in 
ALL. While adult and pediatric ALL 
feature unique characteristics, there 
are several hallmark alterations in T-
ALL including unregulated 
expression of proto-oncogenes, 
chromosomal translocations, and 
tumor suppressor loss (Figure 
2.2)(Pui, Relling et al. 2004).  

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These changes are driven by different genetic mechanisms, which often act 
cooperatively through one or more pathways during different stages of T-cell 
development (Figure 2.3).  
 
T-ALL can be classified into at least five different subtypes based on gene expression 
profiles and specific oncogene activation. Altered NOTCH1 signaling is the most 
prominent characteristic of T-ALL, and more than 50% of all T-ALL cases are found with 
somatic activating mutations or chromosomal alterations that lead to hyperactive 


NOTCH1 activity (Grabher and Harald von Boehmer 2006)(Figure 2.4). 
 
The high prevalence of NOTCH1 alterations in T-Cell has led to considerable 
investigation into the use of gamma-secretase inhibitors as candidates for 

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pharmacological intervention(Grabher and Harald von Boehmer 2006). In addition to 
NOTCH1, deletions of tumor suppressor genes p16/INK4A and p14/ARF via loss of the 
CDKN2A locus at chromosomal band 9p21 are present in more than 70% of T-ALL 
cases(Van Vlierberghe and Ferrando 2012). Rearrangements of transcription factors 
TLX1, TLX3, LYL1, TAL1, and MLL are also commonly observed in T-lineage 
ALL(Mullighan 2012).  
 
2.A.iii ALL Treatment 
Due to rapid onset of hematopoietic failure and life threatening infections ALL is 
invariably fatal without treatment. As a direct result of many sequential standardized 
research protocols over the past decades, survival rates for ALL have improved 
dramatically since the 1980s. Currently five-year survival rates in children are estimated 
at greater than 85% in recent years and are achieved through two to three year 
treatment protocols of multidrug regimens administered in several phases: induction, 
consolidation, and maintenance (Pui, Sandlund et al. 2004, Gatta, Capocaccia et al. 
2005, Horton and Steuber 2014). While specific regimens depend on risk category and 
immunophenotype, at diagnosis patients often require broad-spectrum antibiotics, 
transfusion support, and correction of metabolic imbalances. This treatment is followed 
by the induction therapy phase, which is designed to place patients into 
remission(Horton and Steuber 2014).  Induction typically involves weekly administration 
of vincristine, daily corticosteroids, and 6-12 doses of L-asparaginase(Dinndorf, 
Gootenberg et al. 2007). In high risk patients, anthracycline may be added to the 
regimen, while imatibib or dasatinib are generally limited to treatment of patients 
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featuring Philadelphia chromosome t(9;22) positive disease(Rives, Estella et al. 2011). 
While rapid response is strongly correlated with favorable outcome, over 90% of 
children and adolescents with ALL enter complete remission at the end of induction 
therapy regardless of initial risk grouping(Gaynon, Trigg et al. 2000, Harms and Janka-
Schaub 2000, Kamps, Veerman et al. 2000, Maloney, Shuster et al. 2000, Pui, Boyett et 
al. 2000, Schrappe, Reiter et al. 2000, Silverman, Declerck et al. 2000).  
Pending achievement of remission, the second major phase of ALL treatment, 
consolidation therapy, is initiated for approximately four to six months, in most cases. 
The goal of this phase is to prevent leukemic regrowth, especially that in which drug-
resistance has emerged. To achieve this, several different drug combinations with 
mechanisms of action distinct from that of induction phase therapies are employed on 
schedules designed to minimize resistance development and maximize synergistic 
efficacy(Harris, Shuster et al. 1998, Lauer, Shuster et al. 2001). These include 
Cytarabine, Methotrexate, Anthracyclines, Alkylating agents, and Epipodophyllotoxins 
with intensification adjustment based upon patients risk of poor outcome(Möricke, Reiter 
et al. 2008). 
Maintenance therapy is initiated after completion of both induction and 
consolidation phase therapy, and usually comprises a regimen of daily 6-
mercaptopurine (6-MP) and weekly methotrexate. This phase of treatment is long term, 
lasting from 24 to 36 months in most patients. In recent years patients receiving pulse 
therapy of vincristine and steroids in addition to 6-MP/methotrexate regimens appear to 
yield a more favorable long-term outcome, although it is still unclear at this point 
whether all patients stand to benefit from this regimen(Conter, Valsecchi et al. 2007, De 
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Moerloose, Suciu et al. 2010). During and after completion of maintenance therapy 
patients are monitored for relapse of disease as well as long-term side effects of their 
treatment. For a more in depth review behind the molecular mechanisms of each drug 
please see chapter 3 and in-depth review Pui et al. (Pui and Jeha 2007) 
 
2.A.iv Relapse to T-ALL 
Relapse to initial treatment arises in approximately 20-25% of children with ALL, 
and represents the second most common cause of cancer related death in 
children(Yang, Bhojwani et al. 2008, Horton and Steuber 2014). In adult patients, in 
addition to the 20% of initial diagnoses that show primary resistant disease, more than 
half of the remaining 80% that achieve remission will ultimately relapse(Larson 2014). 
The majority of relapses occur within 2.5 years of diagnosis in the bone marrow or a 
select few extramedullary sites. Patients relapsing after 2.5 years from diagnosis often 
represent a new leukemia development rather than a relapse of an original 
clone(Larson 2014). When relapse does occur, survival is dependent on a variety of risk 
factors, the strongest of which being the time to relapse following initial diagnosis. 
Patients who relapse within 18 months of diagnosis feature a particularly poor prognosis 
with five-year survival around 20%, while the survival rates of other patients depends 
largely on site, timing, and treatment regimen(Nguyen, Devidas et al. 2008). In patients 
who successfully enter remission following clinical induction therapy, monitoring for 
leukemic relapse is conducted through use of blood work, physical examination, and 
bone marrow aspiration at routine intervals. Upon relapse discovery, patients are 




administered in the first round of induction(Locatelli, Schrappe et al. 2012). Such 
therapies include Nelarabine and Clofarabine both of which have shown efficacy in a 
portion of relapse patients. Clofarabine in particular plays an important role by acting as 
a “bridge to transplant” in helping patients to achieve second remission which is 
required for last stage effort hematopoietic cell transplantation (HCT)(Borgmann, von 
Stackelberg et al. 2003, Larson 2014).  
 
2.A.vi Genomic Mechanisms Underlying Drug Resistance  
While a great deal of effort has been placed on understanding the molecular basis of 
relapse and chemotherapy resistance in ALL, the specific mechanisms mediating 
disease progression, leukemia relapse, and therapy escape remain largely unknown.  
To address these questions we performed whole exome sequencing of matched 
diagnosis, remission and relapse DNA samples from 5 pediatric T-ALL patients 
(Supplementary Table 2.1). 
 
2.B Results and Discussion 
Our initial sequencing panel of 5 pediatric patients identified a mean mutation 
load of 13 somatic mutations per sample (range 5 – 17) (Table 2.1). In total, 60 somatic 
mutations were identified. Of these, 17 mutations were present at diagnosis and at 
relapse, 24 genes were selectively mutated in relapsed T-ALL samples and 19 
mutations were present only at diagnosis. Four out of the five total relapsed cases 
analyzed showed the presence of at least one somatic mutation present also at 
diagnosis, together with secondary mutations specifically acquired at the time of 
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relapse. In addition, 4 out of the 5 cases showed absence of at least one mutation 
marker present at diagnosis during disease progression leading to relapse. 
Somatically mutated genes at diagnosis included known T-ALL tumor suppressor genes 
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

not implicated before in the pathogenesis of this disease. As TP53 mutations have been 
reported in about 10% of` relapsed ALL cases and are associated with a particularly 
poor prognosis(Hof, Krentz et al. 2011).  Three genes encoding proteins involved in 
positive regulation of TP53 signaling at relapse is noteworthy. These alterations include 
TP53 itself (TP53 R213Q) as well as mutations in the genes BANP (BANP 
H391Y)(Jalota, Singh et al. 2005) and RPL11 (RPL11 R18P)(Jalota, Singh et al. 2005, 
Zhang, Ding et al. 2012). As TP53 plays an important role in DNA damage driven cell 
death response, an extended mutation analysis of the TP53, BANP and RPL11 genes 
was conducted in 18 additional diagnostic and relapsed T-ALL samples 
(Supplementary Table 2.1)(Bunz, Hwang et al. 1999). While no additional mutations 
were identified in TP53 or BANP, this analysis successfully identified the presence of 
two somatic mutant alleles in gene RPL11. Of these mutations, one (RPL1 X178Q) was 
found mutated at both diagnosis and relapse, while the other mutation (RPL11 G30fs) 
was found exclusively at relapse(Tzoneva, Carpenter et al. 2013)(Supplementary 
Figure 2.1).  
Other interesting relapse specific mutations identified by this study include a well 
known activating mutation in the NRAS oncogene (NRAS G13V). NRAS mutations in 
ALL have been associated with poor outcome and are particularly prevalent in early T-
cell precursor ALLs, a group of high risk leukemias with poor prognosis(Lubbert, Mirro 
et al. 1990, Coustan-Smith, Mullighan et al. 2009, Van Vlierberghe, Ambesi-Impiombato 
et al. 2011, Zhang, Ding et al. 2012). Extended mutation analysis conducted by 
collaborators of NRAS revealed an additional two mutations prototypical activating 
mutations present in three matched T-ALL pairs. Mutation NRAS G12S was found in 
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two matched diagnosis/relapse pairs while NRAS G12R mutant was identified at 
diagnosis and then exhibited loss of heterozygosity at time of relapse(Tzoneva, 
Carpenter et al. 2013).  
The most remarkable finding in our exome sequence analysis, however, was the 
identification of a relapse-specific heterozygous mutation in the NT5C2 gene (NT5C2 
K359Q)(Spychała, Madrid-Marina et al. 1988, Oka, Matsumoto et al. 1994). NT5C2 is a 
ubiquitous enzyme that functions to catalyze the final dephosphorylation of 6-
hydroxypurine nucleotide monophosphates such as IMP, dIMP, GMP, dGMP and XMP 
before they can be exported out of the cell (Table 3.2). Due to its catalytic preference 
for hydroxypurine nucleosides structures, NT5C2 has been shown to have activity on 
several purine based nucleoside analogues utilized therapeutically in the treatment of 
cancer, including T-ALL treatments 6-mecaptopurine (6-MP) and 6-thioguanine (6-TG). 
As NT5C2 may be capable of deactivating the active metabolites of these drugs (6-
thioinositol monophosphate and 6-thioguansine monophosphate) through 
dephosphorylation, it was hypothesized that a mutated NT5C2 enzyme could potentially 
lead to drug resistance(Petter Jordheim and Chaloin 2013). In order to assess if NT5C2 
mutations were prevalent in ALL an extended panel of 98 relapse T-ALL and 35 relapse 
B-precursor ALL samples was conducted (Supplementary Table 2.1). This panel 
identified 22 additional mutations in T-ALL and one additional NT5C2 mutation in a B-
precursor ALL patient in first relapse (Table 2.3). Strikingly, 13 of these samples 
harbored the same NT5C2 R367Q mutation, 4 cases showed a recurrent NT5C2 







Moreover, NT5C2 mutations were acquired exclusively in relapse samples of each of 
the 9 cases for which original diagnostic DNA was available for analysis. Upon 
investigation all 23 T-ALL and 27 B-precursor ALL additional diagnostic samples no 
NT5C2 mutations were found, further supported the specific association of NT5C2 
mutations with relapsed disease. Analysis by Ferrando Lab collaborators of clinical and 
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molecular features associated with NT5C2 mutant relapsed T-ALLs treated in Berlin 
Frankfurt Münster (BFM) group based clinical trials (ALL-BFM 95, ALL-BFM 2000, 
COALL 06-97, NHL-BFM 95 and Euro-LB 02) (Supplementary Table 2.1) showed an 
association of NT5C2 mutations with early disease recurrence (very early or early 
relapse vs. late relapse, P <0.05) and relapse under treatment (P = 0.002) 
independently of treatment protocol (Supplementary Tables 2.2-2.7). Given the 
described role of NT5C2 in the metabolism and inactivation of nucleoside analog drugs; 
the recurrent finding of the NT5C2 R367Q, NT5C2 R238W and NT5C2 L375F alleles; 
and the reported association of increased levels of nucleotidase activity with thiopurine 
resistance and worse clinical outcome, we hypothesized that relapse-associated NT5C2 
mutations may represent gain of function alleles with increased enzymatic 
activity(Pieters, Huismans et al. 1992, Galmarini, Jordheim et al. 2003, Brouwer, 
Vogels-Mentink et al. 2005, Hunsucker, Mitchell et al. 2005). To assess this possibility 
each of the initial three identified mutations with structural coverage was first analyzed 




The positions of each mutation revealed that not one of the mutations occurred in 
close proximity (<6Å) to the enzyme’s substrate-binding site or yielded any obvious 
impacts that might disturb the enzyme’s catalytic active site machinery. To further 
assess the potential functional effects of the identified NT5C2 mutations, the structure of 
each mutant protein was modeled for comparative analysis against several high-
resolution crystal structures of the NT5C2 wild type, both in apo form and that depicting 
the binding of various ligands and effectors (Table 3.2). Overall, models built for the cN-
II mutants R291W, R367Q, and K359Q exhibited no gross global topology changes. 

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Comparison between the distances of electrostatic interactions in the wild type and 
mutant structures suggest a retained active site pocket that is capable of binding NMPs. 
Most notably, all three-mutation models predict negligible structural change to critical 
sites Asp52 and Asp54, suggesting that the mutations do not impact the wild type 
function of these residues directly (Figure 2.7).  
Detailed structure-function analysis of the NT5C2 K359Q mutation further 
supported the hypothesis of mutational activation. Comparison of the wild-type NT5C2 
structure and models of the mutant NT5C2 K359Q protein showed that this mutation 
could result in increased NT5C2 activity by mimicking the effect of positive allosteric 
regulators (Fig. 2.6). Allosteric activation of NT5C2 is mediated by binding of ATP, 
dATP, diadenosine tetraphosphate (Ap4A) and 2,3-bisphosphoglyceric acid (BPG) to an 
allosteric pocket proximal to the NT5C2 active site (Wallden and Nordlund 2011). 
Occupancy of this regulatory site results in increased ordering of an alpha helix formed 
by residues Gly355–Glu364 (helix A/alpha), which in turn displaces Phe354 from the 
catalytic center and moves Asp356 into the active site of the protein (Fig. 2.7a,c) 
(Wallden and Nordlund 2011). Similarly, the mutation model predicts that the NT5C2 
K359Q mutation could increase the stability of helix A and reduce its solvent 
accessibility, resulting in an active configuration with displacement of Phe354 out of the 





Analysis of R367Q and R291W mutation models yielded no obvious mechanism 
of altering regulation of or increasing NT5C2 activity. Interestingly both sites feature 
solvent exposed orientations, directed away from NT5C2 activity centers. To assess if 
either mutation affected enzyme dimerization, the mutant models R367Q and R291W 




comparison revealed no appreciable structural changes to the monomer-monomer 
interface (Supplementary Figure 2.2). The R367 site occurs in a solvent accessible 
region not directly involved in monomer-monomer binding and its mutation to glutamine 
was not predicted to alter the interface hydrogen bonding of any nearby residues in a 
manner that might disrupt interface association (Supplementary Figure 2.2).  
Consistent with structural predictions, 5'-nucleotidase assays prepared in the 
Ferrando lab by Gannie Tzonvea using NT5C2 K359Q recombinant protein 
demonstrated a 48-fold increase in enzymatic activity compared wild type NT5C2 
(Figure 2.8). Despite the absence of clear structural cues suggesting a role of other 
mutations in NT5C2 activation, nucleotidase activity analysis of NT5C2 R367Q and 
NT5C2 D407A mutant proteins revealed an 18 fold and a 16 fold increase in their 5'-IMP 





Finally, and to formally test the role of NT5C2 mutations in chemotherapy 
resistance the effects of wild type and relapse-associated mutant NT5C2 expression 
were analyzed in the response of CCRF-CEM T-ALL cells to 6-mercaptopurine (6-MP) 
and 6-thyogunanine (6-TG) (Figure 2.9)(Tzoneva, Carpenter et al. 2013). Cell viability 
analysis in the presence of increased drug concentrations demonstrated increased 
resistance to 6-MP and 6-TG therapy in cells expressing NT5C2 K359Q, NT5C2 R367Q 
and NT5C2 D407A compared with empty vector and wild type NT5C2 controls (Figure 
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2.9, Supplementary Figure 2.3, Supplementary Table 2.8). Similar results were 
obtained in the CUTLL1 T-ALL cell line (Figure 2.9, Supplementary Figure 2.3, and 
Supplementary Table 2.8)(Tzoneva, Carpenter et al. 2013). 
 
Finally, Gannie Tzoneva and Arianne Garcia of the Ferrando lab tested the 
effects of relapsed-associated NT5C2 mutations in the response to nelarabine – an 
AraG precursor highly active in relapsed T-ALL– and AraG(Berg, Blaney et al. 2005, 
DeAngelo, Yu et al. 2007, Larson 2007, Sanford and Lyseng-Williamson 2007, 
Gökbuget, Basara et al. 2011). Strikingly, both nelarabine and AraG showed to be 
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equally active in cells expressing relapse-associated NT5C2 mutations compared to 
controls (Supplementary Figure 2.6). 
Prolonged maintenance treatment with 6-mercaptopurine is essential to obtain 
durable remissions in the treatment of ALL(Koren, Ferrazini et al. 1990, Dibenedetto, 
Guardabasso et al. 1994, Relling, Hancock et al. 1999, Lauer, Shuster et al. 2001). This 
is best showcased in low-adherence to 6-mercaptopurine treatment, defined as less 
than 95% compliance, which results in increased relapsed rates and may account for as 
much as 59% of all ALL relapses(Bhatia, Landier et al. 2012). In this context, our results 
highlight the prominent role of relapse-specific mutations in NT5C2 as a mechanism of 
resistance to 6-MP and a genetic driver of relapse in ALL. Collectively these findings 
outline an explanation for relapse in a significant proportion of ALL patients and raise 
important questions regarding its treatment (Figure 2.10)(Cancer Genome Atlas 
2012).Our results are further confirmed by a concurrent study by Meyer et al., which 
identified gain of function mutations in NT5C2 in roughly 10% of relapsed B-precursor 
ALL samples(Aster and DeAngelo 2013, Meyer, Wang et al. 2013).  In addition, and 
most notably, the lack of nelarabine cross resistance in cells expressing activating 
NT5C2 alleles analyzed here suggests that these mutations may not impair the 
effectiveness of nelarabine-based salvage therapies in relapsed T-ALL(Tzoneva, 

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Carpenter et al. 2013). 
 
 
Chapter 3. A unifying model for NT5C2 Relapse Mutation 
Function 
3.A Introduction  
3.A.i. Physiologic Roles    
Nucleotides and nucleosides make up a heterogeneous family of metabolites that 
play a wide range of crucial cellular roles including cellular energy production, cellular 
	
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signaling, and DNA and RNA synthesis(Petter Jordheim and Chaloin 2013). 
Maintenance of homeostatic concentrations and ratios of nucleoside metabolites in the 
cell requires active metabolism by proteins that catalyze modifications of the 
nucleobase, sugar, and phosphorylation of nucleosides (Figure 3.1). 
 
The monophosphorlyation status of nucleosides is controlled by a family of 
proteins called 5’-nucleotidases, which catalyze the hydrolysis of dexoyribo- and 
ribonucleoside 5’-monophosphates (NMPs) into nucleosides and inorganic free 
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phosphate (Figure 3.2)(Bianchi and Spychala 2003, Bogan and Brenner 2010, 
Rampazzo, Miazzi et al. 2010, Meurillon, Marton et al. 2014).  
 
Cytosolic 5’-nucleotidase II (NT5C2) is one of eight human 5’-nucleotidases and 
plays an important role in the regulation of nucleotide pools critical for DNA and RNA 
synthesis(Wallden and Nordlund 2011). NT5C2 is a highly conserved protein with 
widespread distribution both in various organisms and tissues (Supplementary Figure 
3.1)(Itoh 2013). NT5C2’s substrate specificity and tissue distribution suggest that a 
primary role is in the excretion of excess intracellular purine nucleotides through 
dephosphorylation of IMP into diffusible inosine, while other more discreet functions 
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may depend on the absence or presence of regulatory factors(Itoh 2013). Evidence 
exists to suggest NT5C2 plays major roles in the Oxypurine Cycle, hepatic derived 
systemic purine supply, general adenine nucleotide breakdown and intracellular 
adenosine formation, substrate cycling between AMP and Adenosine in hepatocytes, 
and many other physiologic roles(Itoh 2013). This widespread functionality is related to 
NT5C2s central role in the cell of IMP and GMP hydrolysis(Itoh 2013).  
  
3.A.ii NT5C2 Associated Diseases  
One major window into the specific roles of NT5C2 is possible through the study 
of disorders associated with its malfunction. Both overexpression and silencing of 
NT5C2 in various cell types has been shown to have detrimental consequences on cell 
growth and survival(G Tozzi, Pesi et al. 2013). In humans several pathologies have also 
been linked to NT5C2 malfunction. Lesch-Nyhan disease (LND) is caused by congenital 
deficiency of the purine salvage enzyme hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) and characterized by hyperuricemia, motor 
disability, spasticity, metal retardation, and self-mutilation(López 2008). While uricemia 
is clearly caused by the absence of HPRT, the mechanisms leading to the 
neurobehavioral abnormalities remain enigmatic. ZMP is a natural intermediate of the 
purine biosynthetic pathway and a considerable increase in Z-nucleotides (ZMP, ZDP, 
and ZTP) has been observed in LND patients (López 2008).  Furthermore, patients 
suffering from Lesch Nyhan syndrome, NT5C2 activity is near doubled in fibroblasts and 
erythrocytes(Pesi, Camici et al. 2008). This activity increase is linked to the production 
of AICAriboside (Z-riboside) at levels leading to neuronal toxicity, suggesting that the 
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neurological manifestations of Lesch Nyhan may be due to NT5C2 mediated 
dephosphorylation of  ZMP (Garcia-Gil, Bertini et al. 2006). Although it has not been 
linked experimentally to NT5C2 directly, Z-riboside is also found in increased 
concentrations in the urine of patients with relapsed ALL. In a study examining Z-
riboside in 10 leukemic children, Z-riboside present in urine was found to differentiate 
between leukopenia of relapse and that of drug toxicity, and may act as a predictor of 
leukemia relapse even prior to other methods of diagnostic detection(Lulenski, 
Donaldson et al. 1970). These findings suggest that NT5C2 is hyperactive in both 
Lesch-Nyhan disease and at relapse in T-ALL patients. Strikingly, incubation of human 
lymphocytes with Z-riboside induces ZMP accumulation and apoptosis in B-
lymphocytes exclusively (Campàs, López et al. 2003). T lymphocytes are unaffected by 
this accumulation, and accordingly in LND patients, which also exhibit accumulation of 
ZMP, have low levels of B lymphocytes but normal levels of T lymphocytes(Allison, 
Watts et al. 1975). While providing drug resistance in both cases, NT5C2 hyperactivity 
in ALL may, therefore, be more taxing on transformed B-cells. This possibility provides a 
potential explanation for the seemingly higher frequency of NT5C2 mutations amongst 
T-ALL samples (19%) when compared to relapse in B-ALL (3%). Although experimental 
validation is required to assess these speculations, what is clear is that NT5C2 exhibits 
a wide range in substrate specificity. This promiscuity may play an unforeseen role in 
diseases or treatment regimens involving purine or purine-like compounds. One 
interesting note is that in Lesch-Nyhan disease NT5C2 hyperactivity is observed in the 
absence of NT5C2 mutations. This suggests that HPRT loss in some way leads to 
hyperactivity of NT5C2. Elucidating the signaling network behind this feedback may 
		
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identify additional mechanisms of increased NT5C2 activity relevant to ALL relapse. It is 
likely that some of the patients lacking NT5C2 mutations still achieve NT5C2 
hyperactivity and drug resistance through mutation in a protein of LND network.  
In the opposite direction, loss of NT5C2 function is also characterized by severe 
phenotypes both in experimental models and human patients. Hereditary spastic 
paraplegias (HSP) are a group of neurodegenerative disorders characterized by age-
dependent loss of corticospinal motor tract function. While a global understanding of 
HSP is lacking, several genetic variants present in NT5C2 have been linked to these 
pathologies(Novarino, Fenstermaker et al. 2014). Purine nucleotides play a critical role 
in protecting the ischemic and developing brain, and it is believed alterations in their 
levels can sensitize neurons to stress and insult leading to motor neuron 
degeneration(Novarino, Fenstermaker et al. 2014). Familial studies of spastic 
paraplegia have identified several NT5C2 variants including a homozygous R29X 
nonsense mutation, a homozygous frameshift and premature termination 
(Ser409Valfs436Ter), a homozygous R149X nonsense mutation, an acceptor splice site 
mutation (c.988-1G-T), and a homozygous donor splice site mutation (c.175+1G-
A)(Novarino, Fenstermaker et al. 2014). All of these mutations are predicted to be loss 
of function, and highlight the devastating effects of NT5C2 loss. In addition to HSP, 
NT5C2 germline variants have been identified in less defined roles involving genetic 
predisposition to higher blood pressure, increased coronary artery disease risk, and 
reduction of visceral and subcutaneous fat(Hotta, Kitamoto et al. 2011). While still 
enigmatic, these associations warrant further study to unravel how the central role of 





3.A.iii Substrate Specificity and Kinetics of Activity 
NT5C2 is capable of both hydrolysis and phosphotransferase activity and acts 
preferentially to catalyze the removal of phosphate of 6-hydroxypurine nucleoside 5’-
monophosphates resulting in the creation of soluble 6-hydroxypurine nucleosides and 
either inorganic phosphate (hydrolysis activity) or a newly furnished nucleoside 
monophosphate acceptor (phosphotransferase activity)(Figure 3.2).   
In general, NT5C2 shows hydrolysis activity on a wide range of 6-hydroxypurine 
nucleoside 5’-monophosphates, but a clear preference for substrates IMP/dIMP and 
GMP/dGMP. Despite this, NT5C2 is a ubiquitous enzyme and is able to catalyze the 
final dephosphorylation of many 6-hydroxypurine nucleotide monophosphates such as 
IMP, dIMP, GMP, dGMP and XMP before they can be exported out of the cell. Table 
3.1 displays the reaction velocities  for various NT5C2 substrates, illustrating both the 
	
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3.A.iv Role of Effectors on NT5C2 Kinetic Parameters 
Allosteric effectors of NT5C2 directly impact enzymatic activity, hydrolase-to-
phosphotransferase ratio, and substrate preferences, adding greatly to the complexity of 
NT5C2 regulation (Itoh 2013). While most allosteric effectors feature a similar 
nucleobase chemical structure, a wide variance is seen in allosteric effect; a full list of 
effectors and relative activity on IMP and AMP hydrolysis is shown in (Table 3.2)(Itoh 
2013). Among purine and pyrimidine nucleotides, ATP and dATP are most effective 
activators of IMP hydrolysis, suggesting that the cellular adenylate energy charge 
([ATP] +.5[ADP)/([ATP] + [ADP] +[AMP]) plays a critical regulator role of NT5C2 
activity(Atkinson 1968, Itoh 1981, Allegrini, Scaloni et al. 2004, Itoh 2013).  These 
regulatory properties tie NT5C2 activity directly to ATP hydrolysis, allowing for excess 
IMP to be removed under high cellular adenylate charge conditions, but acting to 
conserve precious purine molecules by allowing IMP accumulation in the face of excess 
ATP hydrolysis (Tozzi, Camici et al. 1991, Zimmermann 1992, Itoh 1993, Pesi, Baiocchi 
	

et al. 1998, Allegrini, Scaloni et al. 2004).  
 
 
Each monomer subunit contains a substrate binding active site and at least two 
allosteric effector-binding sites(Walldén, Stenmark et al. 2007).  Crystallization of 
effector bound protein has revealed that allosteric activation is achieved through 
activator-mediated stabilization of a critical alpha helix, helix A or helix . This helix acts 
as a conformational switch for enzyme activity: its ordering shifts critical amino acids of 
the substrate binding active-site into an active conformation, while its disordering leads 
to steric hindrance of nucleoside monophosphate binding (Figure 3.2)(Wallden and 
Nordlund 2011). The equilibrium of helix A between helical and disordered secondary 
structure is suggested to be the pivotal determiner of NT5C2 activity(Wallden and 
Nordlund 2011). The propensity for various effectors to increase enzyme activity are 
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directly related to their ability to shift helix A equilibrium towards an ordered state 
(Figure 3.3c)(Wallden and Nordlund 2011).  In the opposite direction, inorganic 
phosphate acts as an allosteric inhibitor of enzyme function by increasing enzyme Km 
and decreasing Vmax (Figure 3.3b)(Itoh 2013). While physiologic allosteric inhibitors 
have yet to be identified, synthetic studies have identified several classes of molecules 
capable of inhibition via competitive binding, albeit none with feasible in-vivo application 






3.A.v Impact on Non-physiologic Nucleotide Analogues 
Nucleotide and nucleoside analogues, compounds that mimic the chemical 
structure, physiologic uptake, and metabolism of natural nucleotide and nucleosides, 
have been explored extensively for use in anti-viral and anti-cancer cell based therapies 
(Meurillon, Marton et al. 2014). While it is well understood that analogue therapies must 
compete with endogenous nucleotides to obtain these effects, the relationship between 
the size of endogenous nucleotide pools and therapeutic effect of these drugs is poorly 
understood. Due to its preference for hydroxypurine nucleosides structures, NT5C2 has 
been shown to have activity on several purine based nucleoside analogues utilized 
therapeutically in the treatment of cancer and viral diseases(Wallden and Nordlund 
2011). Banditellie et al. first confirmed this through showing that NT5C2 with dGMP as a 
phosphate donor was able to phosphorylate several nucleosides and nucleoside 






The clinical relevance of NT5C2 based therapy interference has since been well 
documented in several studies including acute myeloid leukemia (AML), high risk 
myelodysplstic syndrome, B-cell chronic lymphocytic leukemia (B-CLL), T-cell acute 
lymphoblastic leukemia/lymphoma, and B-cell acute lymphoblastic leukemia/lymphoma 
(B-ALL), but is likely to be relevant to all conditions treated with cytotoxic nucleoside 
analogues(Gallier, Lallemand et al. 2011, Petter Jordheim and Chaloin 2013). In 




apoptosis in human astrocytoma cells, which further suggests the relevance of NT5C2 
as a therapy target. Most pertinent is our own identification of NT5C2 in a panel of 
relapse acute lymphoblastic leukemia patients, where we demonstrated that NT5C2 
plays a direct role in drug resistance to the chemotherapy nucleoside analogue drugs 6-
mercaptopurine and 6-thioguanine (Figure 2.9, Figure 3.4c)(Tzoneva, Carpenter et al. 
2013). Due to a defined role in toxicity and resistance to nucleoside analogue therapy, 
NT5C2 is an attractive molecular target in the goal of preventing cancer patient relapse 
(Supplementary Table 3.1). To understand further how NT5C2 may act on these 
therapies it is necessary to understand the structural basis for NT5C2 mediated 
catalysis.  
 
3.A.vi NT5C2 Inhibitor Development 
Given its role in both disease and resistance to anti-cancer and anti-viral 
therapies, the need of NT5C2 inhibitors has become increasingly apparent.  
While pharmacological inhibitors of other nucleotidases have existed for some 
time, NT5C2 inhibitors have only been developed recently and are still not 
feasible for pre-clinical trials and application in patients. Apart from inorganic 
phosphate, the first discovered inhibitors described were 5’-deoxy-5’-
isobutylthioadensoine (IBTA) and 5’-deoxy-5’-isobutylthioinosine (IBTI). These 
compounds were shown to inhibit NT5C2 activity by 50% but only at relatively 
high concentrations (2-6mM and 7-10 mM for IBTA and IBTI, respectively) 
(Skladanowski, Sala et al. 1989, Petter Jordheim and Chaloin 2013). Additionally, 




5’nucleotidase and AMP-specific soluble 5’nucleotidase, two critical enzymes for 
purine nucleotide pathways. More recently, substrate analogue based in silico 
approaches identified several potential ribonucleoside phosphonate analogues 
as inhibitors of NT5C2. These compounds feature a non-hydrolysable bond that 
prevents their dephosphorylation by NT5C2 upon binding and act competitively 
with NT5C2’s native substrates. In vitro screening of these compounds showed 
that beta-hydrozyphosphonates of cytosine and inosine induced 60% and 100% 
inhibition at 250uM and 1mM respectively. These molecules however, are too 
hydrophilic to pass the cellular membrane and thus require pro-drug manipulation 
and improvements in binding affinity. A second major study in 2013 utilized 
additional in silico screening and identified an anthraquinone derivative (AdiS) 
that was shown to block enzyme activity with a Ki of 2.0mM through competitive 
inhibition of NT5C2s active site. In subsequent cancer cell-line assays, AdiS 
showed synergy with cladribine and additivity with Clofarabine and increased 
induction of apoptosis. While demonstrating the utility of virtual screening, AdiS 
remains is not potent enough and requires additional structural optimization. As 
all of these compounds require high concentrations for in vitro inhibition, no in 
vivo experiments have yet been performed and many questions still exist 
regarding delivery, off target effects, and toxicity(Gallier, Lallemand et al. 2011).  
 





NT5C2 forms a dimer-of-dimers in which four monomers combine to form a 
tetrameric quaternary structure (Wallden and Nordlund 2011) (Figure 3.5.b). Interface A 
(alpha), which facilitates the association of two monomers into a dimer, is formed 
through salt-bridges and hydrogen bonding made by fifty three amino acids (Figure 
3.5.a). Interface B (beta), in-turn, facilitates the binding of two identical dimers through 
the interaction of 28 amino acids to form the active tetramer described by Wallden et al. 
(Figure 3.5.c)(Walldén, Stenmark et al. 2007, Pesi, Allegrini et al. 2010).  
 
3.A.vii.a Active Sites and Core Mechanics 
NT5C2 is a member of the haloacid dehalogenase (HAD) superfamily, and each 
monomeric protein of its global structure is defined by the presence of three main motifs 





(DXDX[T/V]L), motif II ([T/S]), and motif III (K(Xx)D(X)0-4D) are positioned by an /-
Rossmann-like domain containing eight-stranded antiparallel sheet surrounded by 
eight  helices (Petter Jordheim and Chaloin 2013). These three motifs come together 
in space to create the active site of NT5C2, which allows binding of substrate phosphate 
to coordinated Mg+2 in a similar manner to that seen in other nucleotidases. In the 
ligand/effector bound cN-II structure, the nucleoside moiety is stabilized by electrostatic 
interactions with Asp206 and Arg202, and stacking between aromatic residues Phe157, 
His209, and Tyr210.  These sites position the nucleoside for nucleophilic attack by 
residue Asp52 on the phosphate moiety of the substrate, and the subsequent donation 
of a proton by Asp54 to the departing nucleoside product (Wallden and Nordlund 2011). 
3.A.vii.b Effector Sites and Allosteric Regulation  
The reaction rates of both phosphate transfer and nucleotidase activity are 
impacted greatly by allosteric regulation through at least two effector sites. In the initial 
solved structures of NT5C2 adenosine was bound to two unique locations, leading to 
the identification of two putative effector sites termed effector site 1 and effector site 2, 
respectively(Tzoneva, Carpenter et al. 2013). Effector site one (ES1) occupies a space 
in close proximity to subunit interface, approximately 20Å from the phosphate moiety of 
IMP bound to the enzymes active site and has been has been crystalized with effectors 
ATP, dATP, Ap4A, and 2,3-BPG bound with full occupancy (Wallden and Nordlund 
2011). The underlying structural mechanism of allosteric regulation through effector site 
1 is a disorder-to-order transition in the helix (termed helix ) formed by residues 
Gly355-Glu364 (Figure 3.3c, Supplementary Figure 3.2). Structural alignment 




illustrate the presence of an ordered helix  occurring exclusively in the NT5C2 active 
form (Figure 3.6b,c).  The ordering of helix  shifts residue Phe354 from the active site 
region into the effector site 1 pocket and transitions Asp356 into the active site of the 
protein; these movements induce a series of rearrangements that transform the enzyme 




The role of effector site 2, however, remains unclear. Although this cavity site has 




bind ATP, Ap4A, dATP, or 2,3BPG to this site in a later crystallographic paper(Walldén, 
Stenmark et al. 2007, Wallden and Nordlund 2011). Studies designed to further 
investigate the role of effector site 2 found that upon mutagenesis of residue H428D 
NT5C2 became unresponsive to any of its described effectors, exhibiting complete 
impairment of enzyme regulation(Pesi, Allegrini et al. 2010). In their 2011 paper, 
Wallden et al. utilize a catalytically dead mutant (D52N), and particular conditions, which 
may prevent the binding of effector to this site (Figure 3.7). Alternatively, as this site 
was crystalized bound to adenosine but not ATP, it is possible that effector-site-2 may 
be specific for an effector not investigated(Wallden and Nordlund 2011). While the 
precise role of effector site 2 remains unresolved, its disruption of allosteric control upon 
mutation highlights the need for additional study(Pesi, Allegrini et al. 2010). 
 




While the C-terminus of NT5C2 is probably the least well understood portion of 
the protein, it contains many regions of interest including highly mobile disordered linker 
regions, redox control switches, and a striking 13 residue long C-terminal acidic 
stretch(Bretonnet, Jordheim et al. 2005). The acidic tail of NT5C2 is present in all forms 
of the enzyme and is highly conserved with particular orthologues displaying extensions 
of the negative motif by 9 additional glutamate residues (Supplementary Figure 
3.3)(Bretonnet, Jordheim et al. 2005). The function of this region has been analyzed 
through mutated constructs where contradicting results have been recorded. Originally, 
deletion of the trailing 13 acidic amino acids of NT5C2 was reported to yield 20-fold 
decreased expression, a 2-fold increase in Km and 20-fold decrease in specific activity, 
and altered the quaternary structure of the enzyme from a tetramer to a monomer 
(Spychala, Chen et al. 1999, Walldén, Stenmark et al. 2007). In contrast, other studies 
measuring nucleotidase activity of bovine NT5C2 with a 35-residue truncation displayed 
no difference in enzyme activity. A separate study utilized two constructs, one which 
lacked the terminal 25 residues and another which lacked the final 12 terminal residues, 
and found that neither truncation affected expression or quaternary structure(Walldén, 
Stenmark et al. 2007). Our unpublished results depict a similar finding in that removal of 
the C-Terminus has limited effect on nucleotidase activity (Spychala, Chen et al. 1999). 
These contrasting results may arise from experimental differences as each assay 
utilized slightly different forms of the protein(Bretonnet, Jordheim et al. 2005). 
Three positive regions of NT5C2 structure hold the electrostatics to potentially 
interact with the negative tail stretch: (K(25)KYRR), (K359)SKKRQ), and 




suggest that (K(359)SKKRKQ), which comprises most of helix alpha, binds to effectors 
at effector site 1 and that the (Q(420)RRIKK) positive-site may, at least in some 
situations, be responsible for binding to effectors at effector-site 2. The most likely C-
terminal interactor, therefore, is the third stretch (K(25)KYRR) stretch, although this has 
yet to be confirmed experimentally (Supplementary Figure 3.4)(Walldén, Stenmark et 
al. 2007). 
 
In addition to its conserved negative cap, the C-terminal tail also includes 
mechanisms to provide sensitivity to oxidizing conditions(Allegrini, Scaloni et al. 2004). 
Disulfide bridge formation between residues C175 and C547 have been confirmed by 
Edman degradation of purified disulfide-containing peptides(Allegrini, Scaloni et al. 
2004). Additionally, two forms of the NT5C2 protein have been described in physiologic 
conditions through use of MALDI-TOF analysis(Allegrini, Scaloni et al. 2004). One of 
these which features a truncation at AA 526 no longer displays sensitivity to changes in 
redox conditions, further evidencing the presence of a redox control switch at AA 547 of 
the NT5C2 C-terminus. Whether these differences constituted valid physiologic controls 
or experimental artifacts requires further study, particularly into the structural nature of 
the C-Terminal stretch AA480-560(Bretonnet, Jordheim et al. 2005). Despite a cytosolic 
location, NT5C2 has a particularly poor solubility making crystallization of the full-length 
protein difficult. Due to this, in all NT5C2 structures, including homologous cN-II in 
Legionella pneumonia, the C-terminal region is truncated by 25 amino acids and 
containing approximately 487 ordered residues. In context of the NT5C2 tetramer, this 
approximately yields 320 absent amino acids per tetrameric unit (Figure 3.8). Given the 
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potential role of the acidic stretch in the C-terminus and redox switch these crystalized 
representations provide an incomplete picture of the enzymes regulation, warranting 
further crystallographic study. 
 
3.A.viii. Mutation Impact 
Collectively, the development of NT5C2 inhibitors has yet to yield a 
molecule capable of inhibition at physiologically relevant concentrations, 
deliverable chemical structures, or required specificities. Additionally, all 
compounds screened thus far act through competitive inhibition at the enzymes 
active site by mimicking nucleoside monophosphate structure to out-compete 
substrate (Meurillon, Marton et al. 2014). As NT5C2 shows considerable 
substrate overlap with many enzymes, these current inhibitor schemes run 
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considerable risk of unwanted side effects due to lack of specificity. Further 
complicating development, familial cases of HPS highlight the severe side effects 
associated with systemic loss of NT5C2 activity. This disorder provides the 
rationale that even perfectly specific NT5C2 inhibition via competitive means runs 
high risk of major toxicity. The pharmacological properties of an effective 
competitive inhibitor must adhere to a remarkably tight window to avoid these 
toxicities and still retain therapeutic value (Petter Jordheim and Chaloin 2013). 
HSP patients have thus far been identified with homozygous loss of NT5C2, 
suggesting loss of both copies is correlated with pathology. On the other hand, 
heterozygous family members display no obvious phenotype, suggesting that the 
presence of one functional NT5C2 gene can avoid toxicity. The development of 
inhibitors that are specific for hyperactivated mutated NT5C2 exclusively, 
therefore, hold the potential to avoid many toxicity concerns. Although the 
development of this specificity is possible, no identified NT5C2 mutations occur 
within the substrate-binding region of the protein, suggesting that the competitive 
inhibitor schemes developed thus far are incapable of optimization into mutation 
specific inhibitors. Collectively, these issues create a significant obstacle to the 
therapeutic use of NT5C2 competitive inhibitors. A much more attractive option, 
therefore, is the development of allosteric inhibitors. While the substrate-binding 
site of NT5C2 is highly conserved amongst homologous proteins, the remaining 
structure of the protein shows much higher variation. This property makes the 
task of NT5C2 specific inhibitor development more achievable, as less structural 
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homology reduces the likelihood of off target binding. Most notably, allosteric 
modes of inhibition allow for the possibility of mutant NT5C2 specific inhibitors 
that can act to down regulate drug resistance but avoid toxicity attributed to 
complete loss of NT5C2 activity such as in HPS patients. While robust structural 
work has uncovered the role of effector-based activation in NT5C2, no known 
allosteric mechanisms of inhibitory function have yet been discovered. The 
identification and structural characterization of such a site is critical towards the 
development of optimal inhibitors. 
 
Despite the identification of multiple recurrent relapse associated mutations in 
relapsed ALL patients, it remains unclear how these site-specific alterations change 
NT5C2 function on molecular level. Following the publication of our 2013 paper in 
Nature Medicine, follow up sequencing identified an additional set of NT5C2 mutations. 
Up to this point, we have identified 26 non-silent unique mutations in more than 56 





While preliminary work on mutation K359Q, which occurs directly in known regulatory 
region helix alpha, suggests a clear mechanism of activation, the remaining mutations 
identified do not display an obvious connection to NT5C2’s core machinery (Figure 
2.7). The leading findings on NT5C2 structure-function suggests that helix  must be 
ordered in helical structure for NT5C2 to be active(Wallden and Nordlund 2011). 
Therefore, I hypothesized that to have an activating effect on enzyme catalysis, each 
mutant must 1) increase the ordering propensity of helix , 2) remove a dependence 
upon it, or 3) prevent dimerization of NT5C2 monomers altogether. Here through robust 
structural analysis of the NT5C2 protein and each mutant I present a unifying model for 
NT5C2 hyperactivity in T-ALL relapse. Additionally, through the characterization of a 
novel allosteric regulatory mechanism, I enable for the first time the potential for the 
rationale design of an allosteric and mutation specific NT5C2 inhibitor. 
 
3.B Results and Discussion 
 
3.B.i Mutant Categorization  
As a first-pass approach to identify potential mechanisms of function for both the 
previously published and newly discovered NT5C2 relapse mutations, regions of 
potential interest on the NT5C2 monomer were categorized. These regions include the 
NT5C2 active site, effector-site 1, effector-site 2, C-terminal tail, and also a previously 
undescribed region of the protein formed by two amphipathic alpha helices (L375-400, 




extension (DHE domain) of approximately 58 residues (AA 375-433) is present in all cN-
II structures in a helix-disordered loop-helix format. 
 
Each identified relapse mutant was then overlaid on the molecular surface of 
active NT5C2 2XCW and binned into one of the structural regions described in Figure 
3.9. While two mutations occur directly within the regulatory helix , the monomer 
protein overlay reveals no obvious clustering of the remaining mutations to any 
particular region (Figure 3.10).  As previously found with the first three identified 
mutations, not one of the newly discovered mutations occurs in close proximity to the 





As NT5C2’s active physiological state is a tetramer, and it has been previously 
shown that the NT5C2 dimer is the minimal quaternary structure with enzymatic activity, 
I hypothesized that the mutations might cluster in a more intuitive fashion when overlaid 
on a physiologic structural representation of the NT5C2 protein (Figure 3.11)(Pesi, 
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Allegrini et al. 2010). 
 
 
Upon analyzing this new quaternary format, a new categorical region of the 
protein became apparent: a cavity created by monomer-monomer interface A (Figure 
3.12).  This cavity occurs directly beneath the DHE domain and proximal to effector site 
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2 of one monomer while its opposing wall is formed by residues backing into helix  of 
the respective opposing monomer (Figure 3.12). In order to characterize this cavity 
quantitatively the surface topography of the NT5C2 dimer was computed using a 1.4-
angstrom probe. Interestingly, CasTp analysis suggest that the dimer interface forms a 
channel which terminates into a mirror image pocket on both side of the dimer. This 
channel highlighted a molecular surface (MS) volume of 8356.8 Å, and solvent-





To assess the position of mutations within the correct quaternary structure, each 
mutation was overlaid onto four monomers arranged in the biologically relevant 
positioning of the tetrameric structure. Overlay of the mutations on to the dimer structure 
reveals a distinct clustering of mutants in and around this dimer interface cavity, 
suggesting it may play a direct role in enzyme activation or control (Figure 3.13). Also 
evident is a second cluster of two mutations to helix  (Figure 3.13).  
 As 
overlay of the quaternary structure yielded novel categorization patterns, each relapse 
mutant was re-categorized into several novel groups: helix , dimer interface cavity, 





An interesting observation about many of the mutations is that their native wild-
type amino acids have limited contact with surrounding residues and, instead, point into 
the space of the cavity. This is true for mutation sites R39, R367, S445, R446, R238, 




Interestingly, the region of disorder in the DHE domain loop (400-420) also 
seems to be oriented into the interface cavity interior. This motif region varies widely 
between individual NT5C2 structures, suggesting that the region is highly dynamic 
(Table 3.4). The DHE domain is formed by two helical extensions that form “arms” to 
position a disordered loop region of varying size. Table 3.4 specifies the length of the 
DHE disordered loop region, which is the amount of the DHE domain that appears 
unstructured in all NT5C2 PDB crystallizations. The minimum length of this disorder is  
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11 amino acids of the apo structure 2XCX while the maximum loop is 25 amino acids 
long in structures 2XJF and 2XCV (Table 3.4). All structures contain the minimum 
sequence motif LDSSSNERPD, but the function of this region and the reason for its 
disorder remains unclear.  
 
If this region is, indeed, highly mobile, it is possible that the unraveling of the 
helical arms of the DHE domain allows control of interactions by the disordered region. 
In other words, increasing the loop length allows for more flexibility in this area, 
potentially allowing mutation sites D407 S408 to interact with other areas of the protein, 





3.B.ii DHE Loop Pocket Interaction 
To assess the position of the disordered loop region of the DHE domain and it’s 
identified relapse mutation sites D407 and S408, I first set out to confirm the dynamic 
nature of this region by analyzing the -factor of its available crystallizations. -factor is 
a representation of thermal motion, and thus to test the hypothesis that the disordered 
loop region is truly dynamic in nature its  -factor should exhibit relative increase with 
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regard to the rest of NT5C2. To assess -factor of this region, the thermal motion of 
structure 2XCW was analyzed through a render by attribute depiction of the NT5C2 
structures. Each NT5C2 PDB file includes -factor data which can be read in and be 
color mapped along a histogram of -factor values that describe the displacement of the 
atomic positions from an average value. For instance, the more flexible an atom is the 
larger its mean-squares displacement from the position will be(Karadaghi 2014).  -
factors are normally between 15 to 30 square Angstroms, but can be higher than 30 in 
more flexible regions. As suspected, the -factor of this NT5C2 structure clearly 
indicates high thermal motion in the DHE domain, particularly the regions adjoined to 






In order to rule out experimental variances during crystallization, the -factor of 
all existing NT5C2 structures, including homologous cN-II Legionella pneumonphila 
(Lp), were analyzed and plotted on their respective structures. Figure 3.18 reveals that, 
indeed, the dynamic loop region displays the highest relative -factor in every structure, 
although the values between structures vary considerably (~30-140+ square 
Angstroms). As these structures all feature the same unit cell organization this 
comparison is valid crystallographically, and suggests that the loop is indeed the most 
dynamic portion of NT5C2 across many different physical states including reservoir 





Given the dynamic nature of this loop, I hypothesized that the disordered loop 
region of the DHE domain (400-420AA) of one monomer may interact directly with the 
residues of the interface cavity formed by both monomers. If valid, this mechanism 
would enable the residues of the DHE disordered loop to “talk” with those in the cavity, 
providing both a means of indirect regulation to helix alpha and an explanation for why 
the mutated cavity residues (R39, R367, S445, R446, R238, and R478) point into the 
interior void of the cavity without clear interaction with surrounding residues (Figure 
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3.16).   
In order to test the feasibility of a loop-pocket interaction I then analyzed the 
electrostatics of the region by calculating the bimolecular solvation of the NT5C2 
structures through use of the Adaptive Poisson-Boltzmann Solver (APBS)(Baker, 
Sept et al. 2001). Results of this analysis yield an interesting electrostatic picture 
of the enzyme, which shows clear regions of distinct charge across its surface 
(Figure 3.19). 
 Of 
note is a concentration of positive charge within the mutated interface cavity. The 
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overt positive nature of this pocket suggests strongly that it is involved in 
electrostatic interactions, particularly due to the outward facing nature many of 
the positive charges (Figure 3.19). Mapping APBS calculations with electrostatic 
potential map compute gird in Chimera allows visualization of these electrostatic 
potential isocontours (kT/e) on the protein molecular surface. When compared 
to the apo structure, highly positive interface cavity becomes clear in active 
structure 2XCW with heavy blue color indicating strong positive potential (~10 
kT/e). This finding suggests that this cavity may display different accessibility 
depending on the enzymes form, as in the apo structure it shows less positive 
potential (3-4 kT/e) (Baker, Sept et al. 2001)(Figure 3.20, Supplemental Figure 




As the majority of the DHE domain loop is disordered in all NT5C2 
structures, the missing sequences were aligned and analyzed through primary 
structure methods. Electrostatic analysis of the disordered loop motif reveals a 
highly specific ordering or polar, negatively charged, and hydrophobic residues 
(Figure 3.21). The ideal positioning of several highly negative residues suggest 
that electrostatic interaction is compatible between the disordered loop and the 
positive cavity pocket (Figure 3.21), while positive residues (K404 and R413) 
provide a restricting influence of the DHE into particular conformations. 
Evolutionary analysis of this motif reveals that this sequence is highly conserved 
through protostomian evolution with invariant conservation through Danio rerio 








3.B.iii Modeling of Di-Helical Extension Disordered Loop 
After confirming the feasibility of loop-cavity interaction at the dimeric interface of 
NT5C2, I then sought to test this interaction further through the use of in-silico molecular 
dynamics and docking algorithms. In-silico modeling of the 19 disordered residues 
(E(399)LYKHLDSSSNERPD) of structure 2XCW reveals the full dynamic range 
of this region by allowing ab-initio folding to explore different conformations 
iteratively in a deterministic fashion. Ranked discrete optimized protein energy 
scores (DOPE), the best 20 models were picked and displayed on the molecular 
structure of PDB 2XCW (Figure 3.24). The DOPE score is an atomic distance-
dependent statistical potential calculated from a sample of native protein 
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structure training sets and it is implemented into the modeling package 
MODELLER as a means of energy evaluation of predicted models(Fiser, Do et 
al. 2000). Interestingly, each model has a different conformation, exhibiting a 
highly dynamic yet restricted movements of the DHE loop within the positive 




As the Apo form 2XCX exhibits the most ordered DHE domain of all 
crystalized structures, and thus the shortest DHE loop, I hypothesized that 
modeling of its disordered region (L(405)DSSSNERPD) would limit pocket 
interaction. The top DOPE ranked loop refinements determined by Modeller, 
confirm a limited pocket interaction and restricted mobility (Figure 3.24). 
Modeling of loop in other structures, confirm that this nature is not unique to 
structure 2XCW. These modeling results suggest that loop-pocket interaction 




As electrostatic interactions between the positive pocket residues and loop 
residues are hypothesized to be driven primarily by negative residue D407, I then 
analyzed the positions of D407 in both set of top ranked model conformations to 
observe this residue. Figure 3.25 shows the difference in range of residue D407 
between Apo and Active structures, highlighting D407’s heavy presence within 
the positive cavity in the IMP bound structure and restricted non cavity position in 





Next, to analyze which cavity residues Asp407 might be interacting with 
directly, I utilized molecular dynamics and stepwise energy minimization to 




By dynamically registering all potential hydrogen bonding and salt-bridge 
opportunities throughout each stepwise motion of the DHE loop, a set of residues 
with electrostatically feasible interaction with Asp407 were identified (Figure 
3.27). Molecular surface representation of these residues, colored by heteroatom 
and charge, shows a distinctive positive path through which D407 may move 
dynamically via stepwise hydrogen bond and salt bridge formation (Figure 3.26). 


Repeating this analysis with the residue S408, S409, S410, N411, and E412 
fragment (D(407)SSSNE(412)) reveals the positive channel created by the 




The most intriguing finding associated with this analysis, occurs upon 
overlay of the mutations onto this positive channel. As shown in Figure 3.29, 
many of the positive channel nitrogen atoms depicted belong to an amino acid 
residue that is mutated at relapse in T-ALL (Figure 3.29, Table 3.3). This 
includes five different mutations: R367Q, R446Q, R39Q, R238W/L, and R478S. 
Concurrently, the residues of the DHE loop predicted to hydrogen bond to these 
positive nitrogen atoms also feature several mutations (Figure 3.29). Collectively 


these findings begin to paint a picture mutation based loop-pocket disruption.
 
While Figure 3.29 demonstrates a strong association between DHE loop and 
interface pocket mutations, how these mutations impacted NT5C2 activity 
remained unclear. As helix alpha must be ordered for NT5C2 to be active, I 
hypothesized that these mutations were acting to shift the equilibrium towards 
the ordered state (Figure 3.30). Helix alpha is, in part, stabilized by hydrogen 
bonding between Aspartic Acid 459 and Lysine 361. Strikingly, in the lowest 
potential energy structure D407 occurs with predicted hydrogen bonding to 







In order to assess if the stabilizing core formed between Asp459, Lys361, 
and Arg39 was destabilized by the presence of Asp407 in its lowest energy 
conformation, the DHE loop was remodeled a second time with eased 
restrictions on helix alpha secondary structure and previous run top structure 
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(Figure 3.31) was used as a starting point. Though far more computationally 
expensive, this modeling run resulted in the highest DOPE scores thus far, and 
depicted many conformations of intermediate transition between ordered and 
disordered helix alpha (Supplementary Files). The intensely close range of 
energy scores for these different conformations suggests that the loop moves 
dynamically through the pocket rather than settling in any one particular position 
(Supplementary Files). This nature is highly supported by  -factor analysis of 
the many crystalized structures of NT5C2 (Figure 3.18).  
Given its dynamic movement, which is initiated only upon active conformation 
(Figure 3.23, Figure 3.24) and its predicted interaction with critical components 
of helix alpha stabilization (Figure 3.31), I hypothesized that the DHE loop may 
act as a negative feedback inhibition mechanism. Upon activation by effectors or 
by random walk, NT5C2 monomers shift conformations slightly and helix alpha 
becomes ordered (Figure 3.6). This ordering is in part stabilized by effectors at 
effector site 1 (Figure 3.6), but also by interactions of Lys361 with Asp459 
(Figure 3.30). Once in this state, the DHE loop gains additional flexibility, as 
predicted by loop refinement (Figure 3.24), and begins to travel along a path of 
positive interface residues through stepwise hydrogen bonding (Figure 
3.27,3.29). Along this path Asp407 comes in contact with K361 potentially 
forming a salt bridge. This bond causes a shift of Asp 459 into more direct 
bonding with Arg367 as seen in apo structure 2XCX (Figure 3.30). The bond 
between residue D407 and K361 is shortly disrupted by interaction with other 
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competing positive cavity residues, but has already provided the necessary 
energy to destabilize helix alpha. Collectively these findings suggest a novel 
negative feedback mechanism where Apo to active (2XCX-2XCW) transition 








Given NT5C2’s indispensible role in in cellular processes via nucleoside 
manipulation, and wide spread tissue distribution, this level of activity control 
seems reasonable(Itoh 2013). More over, these results provide a possible 
explanation as to why NT5C2 structures cannot crystalize with the DHE loop 
bound to the interface cavity, as thermal instability is intrinsic to this region 
(Figure 3.17, Figure 3.18, Figure 3.32). While not definitive without explicit 
experimental verification through additional crystallization, the rational behind this 
model is well supported through many lines of in silico evidence. Even more 
supportive, however, is the nature and positioning of the NT5C2 relapse 
mutations themselves.  
 
3.B.iv Structural Modeling of NT5C2 relapse mutations 
After developing this model of NT5C2 regulation and outlining its close 
association with many of the mutations identified in T-ALL relapse, I then hypothesized 
that the majority of mutations identified in T-ALL relapse would either play a role in 
disruption of the inhibitory mechanism of the DHE loop model or directly impact helix 
alpha itself. To accomplish this, each mutant was first analyzed for charge shift to 




Table 3.3 displays the structural location of each mutation and the amino acid class 
change. Overall, 53 unique cases display a shift of a positive cavity amino acid into 
a non-charged amino acid (Table 3.3, Figure 3.33). Another striking finding is that 
all of the mutations to the DHE loop involving a negatively charged residue alter it 
into either a less negative residue, an uncharged residue, or the insertion of a 
positive residue (Figure 3.33, Table 3.3).  
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
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In order to assess how each mutation might affect NT5C2, a mutant 
structure was modeled using the NT5C2 dimer 2XCW as template. Where 
relevant, the DHE loop was also remodeled along side the introduced mutation to 
assess for changes in this potential inhibitory mechanism. 
 
The most prevalent mutation identified by far is the mutation 
NT5C2_R367Q, which removes a large positive charge from the core 
stabilization area of helix alpha. The modeling of this mutation predicts a few 
interesting new bonding opportunities. First, due to glutamines bivalent nature, 
Q367 it is able to form hydrogen bonding with Asp459 as before, but also a new 
bond directly to Lys361 (Figure 3.34). This bond provides an additional means of 
stabilization for the ordered state of helix alpha. Second, this increased bonding 
would act to reduce the impact of competition from D407, thus making inhibition 
through the DHE loop more difficult to achieve (Figure 3.34). Additionally, many 
conformational models of DHE loop folding suggest that R367 plays a role in the 
stepwise bonding that leads Asp407 into contact with Lys361. As both 
exceedingly active and silenced NT5C2 activity has been shown to cause 
significant cell toxicity, mutants that adhere to a strict window of activity should in 
theory be selected for under presence of nucleotide analogue therapy(Campàs, 
López et al. 2003, Suzuki, Sugawara et al. 2007, G Tozzi, Pesi et al. 2013, Itoh 
2013, Petter Jordheim and Chaloin 2013, Novarino, Fenstermaker et al. 2014). 
For these reasons, an ideal mutation might act to only slightly increase the 
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enzyme’s activity through slight stabilization of helix alpha and mitigation of the 
inhibitory loops effects without causing any major structural disturbances (Figure 
3.34). To support this idea SDM server, which predicts mutations impact on 
protein stability, predicts an overall neutral impact with very slight stabilization 
and a non disease associated pseudo DELTA G of .23 for mutation R367Q 
(Worth, Preissner et al. 2011). A mild increase was further verified through 
NT5C2 experimental activity assay conducted by collaborator Gannie Tzonvea, 
who showed R367Q activating potential to be moderate compared to that of 
other mutations such as K359Q (Figure 2.8)(Tzoneva, Carpenter et al. 2013). As 
K359Q is predicted to highly stabilize helix alpha directly through a different 
mechanism, it is also forth telling that its experimental activity is extremely high 
relatively and its frequency amongst samples extremely low. One possible 
explanation for this is that it has toxic effects on tumor cells that acquire it(Allison, 




Mutations at D407 provide a complementary verification to the logic 
predicting the impact of mutation R367Q. D407A/Y and mutation S408R, would 
both act to disrupt the charged interaction between D407 and K361 either 
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through loss of negative residue or neutralization of negative charge through 
introduction positive arginine. Additionally, both changes may act to prevent 
D407 positioning near K361 entirely by preventing interaction with any positive 




These positive bonding steps are formed by amino acids that are also 
often mutated. This is the case with mutations R39Q, R446Q, R238W/L, and 
R478S, which all involve the loss of a positive charge and thus should act in a 
similar fashion to prevent interaction between residue D407 and K361. SDM 
algorithm assessment of each of these sites again predicts negligible impact of 
Arginine to Glutamine in overall protein stability. As there is no known function for 
any of these sites, and their mutation does not influence overall protein stability, 
the DHE loop model provides a rationale potential explanation for their action. 
(Figure 3.27,Figure 3.32, Figure 3.39).  
The only mutation in the cavity that does not fit this characteristic change is 
S445F. This mutation transforms a polar residue into a very large bulky 
hydrophobic residue directly into the line path of the DHE loop. Through steric 
hindrance this mutation should, ultimately, act much the same as the positive 
pocket mutations by preventing D407’s access to the critical switch residue 
K361. Modeling of this mutation while keeping restriction on the DHE loop 




Mutation D407E at first glance appears to not fit into the model as the rest 
of the mutations because it involves a change of one negative amino acid to 

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another negatively charged amino acid at site D407. Interestingly, upon closer 
analysis, this mutation in-fact helps to provide support for the hypothesis of 
limited activation of NT5C2, as the pK of aspartic acid is .3 less than that of 
glutamic acid. What this means is that glutamic acid spends less time in a 
charged state at physiologic pH, or in other words, the mutated residue is less 
negative than wild-type aspartic acid. Furthermore, glutamic acid contains an 
additional CH2 group that may act to cause steric hindrance to the loop during 
folding.  
Of the two mutations on the edges of the DHE loop motif (P414S and 
K404N), each mutation involves the loss of a key structural point that assists the 
unraveling of the loop into the pocket. Residue K404, forms hydrogen bonding 
with glutamic acid 401. This interaction causes a kinking in the loop and restricts 
its movement into the cavity pocket (Figure 3.37) which results from loss of 
stabilization by hydrogen bonding between K404 and E401, as well as that 
between K404 and the adjacent backbone, by mutation Asn404. Figure 3.37 




In secondary structure, proline plays a particularly important role due to its cyclic 
nature which gives this amino acid exceptional conformational rigidity compared 
to other amino acids. Proline often acts as a disrupter of alpha helices and is 
found at their edge because of its propensity to cause turns in amino acid chains. 
Mutation of P414S, removes this helix cap, and thus allows for the helix to 
continue on, preventing the DHE loop from unraveling into the pocket. This is 
further supported by predict-protein secondary structure assignment between 
both mutations showing a gain of extra length alpha helix (Rost, Yachdav et al. 
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2004). The structural predictions of both of these mutations suggest activation 
roles as they might act to disrupt a negative feedback system.  
This pattern makes sense in light of the proposed loop-pocket mediated 
negative-feedback-loop model, as any loss of positive charge within the track 
could delay the enzymes shutoff (Figure 3.26, Figure 3.32). The hypothetical 
result of such a delay would be a moderate increase in enzyme activity, to a level 
that is hyperactive but still sustainable physiologically(G Tozzi, Pesi et al. 2013). 
This activity profile would mimic the increased Vmax and decreased Km of weak 
effectors, but also retain strong ability to be activated further by effectors such as 
ATP and Ap4A(Itoh 2013).   
The only remaining mutations are those that that do not occur at the 
interface or within the DHE loop. These include K359Q, S360P, and L375F. 
While K359Q analysis confirms published predictions of helix alpha stabilization 
(Tzoneva, Carpenter et al. 2013), mutation S360P works through a slightly 
different although related mechanism.  Proline introduction into alpha helices 
nearly invariantly disrupts helical secondary structure which is why it either starts 
or ends alpha helical regions in most cases. As such, mutation S360P, which 
inserts a proline directly into the center of helix alpha was initially perplexing as it 
should lead to some permanent disorder of the helix. In order to investigate 
further, this mutation was modeled into active and apo NT5C2 structures to 
assess its potential impact on NT5C2 activity and critical alpha helix residues 




mutation suggests that while half of helix alpha is rendered unable to order by the 
kinking nature of P360, the other half retains its secondary structure resulting in 
the positioning of residues D356 and F354 (Figure 3.38). Additionally, the 
predicted model suggests that cross talk from the positive cavity pocket may be 
disrupted by this mutation, as Lys361 no longer retains influence on critical 
residues D351,F354, and D356 (Figure 3.38). This finding suggests that 
mutation S360P also works by indirectly disrupting inhibitory influence, further 






Mutation L375F does not occur directly within any of the outlined structural 
regions such as the positive cavity pocket, negative inhibitory loop, or helix alpha 
itself. However, upon structural mapping and molecular environment analysis it is 
clear that L375 is present within a dedicated hydrophobic pocket formed by 
residues A31, Y32, F36, I372, L375, L379, W382, L440, F441, Y461, A463, and 
H486 of the opposing monomer. These amino acids are responsible for assisting 
dimerization of monomer-monomer NT5C2 interaction (Figure 3.39). Mutation of 
residue L375F to a phenylalanine serves to introduce an additional hydrophobic 
ringed structure to a pocket already stabilized sustainably through pi-stacking 
and hydrophobic interactions (Figure 3.39).  This mutation is predicted to 
stabilize this hydrophobic core further, resulting in a more stable enzyme dimer. 
As NT5C2 requires dimerization for activity and it oligomerization is one mode of 
regulatory control within the cell, this mutation likely hyperactivates NT5C2 by 
increasing the concentration of tetrameric NT5C2 in the cell(Allegrini, Scaloni et 
al. 2004).  In strong support of this hypothesis, a mutagenesis experiment which 
mutate residue F36 to a positive arginine found complete loss of NT5C2 
activity(Pesi, Allegrini et al. 2010). Supplementing this rationale, SDM stability 
algorithm analysis of mutagenesis mutation F36R mutation predicted to highly 
disturb localized protein stability, while not the mutation L375F mutation was 






As every mutation except for L375F and K359Q were predicted to in some 
way disrupt the inhibitory action of the DHE loop on site Lys361, I suspected that 
they should also lead to similar levels of NT5C2 hyper-activity. Indeed NT5C2 
activity assays measuring IMP hydrolysis conducted by collaborator Gannie 
Tzonvea confirms similar levels of hyperactivity for mutations R367Q, S445F, 
S408R, D407A, S360P, and R238W (Figure 3.40). Although this argument only 
considers one parameter and its results could have other explanations, the 
similarity across these different sites in activity is intriguing. Additionally, as 
predicted mutations L375F and K359Q display noticeably larger hyperactivity 
levels, they may indeed work through alternative mechanisms such as those 
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

provided in figures 2.4 and 3.36 (Figure 3.37).
 
A remaining question is that of effector site 2 and how it fits into the predicted 
loop-pocket based inhibition model. Given this sites proximity and predicted 
interaction with the DHE loop in several mid-range scoring models the question 
of this effector-site raises once more. In the active IMP bound NT5C2 structure 
(PDB 2XCW) unphosphorlated DHE loop models, the loops capable of folding 
within the effector-site 2 would presumably compete with a binding of a ligand. 
While the physiologic ligand or ligands for this site are unknown, only one ligand 
(adenosine) has been bound experimentally in crystal structure, 2JC9, which was 
incubated with adenosine during crystallization. In this structure the ribose of 
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adenosine is highly unstructured and its position unclear suggesting adenosine 
may not be the true physiologic ligand for this site. One hypothesis is that 
phosphates are required for full occupancy, and this is supported by the position 
of sulfate molecules, which act to mimic phosphate, in several structures 
structure 2JC9(Walldén, Stenmark et al. 2007). These two sulfates are 
positioned so that they form hydrogen bonding with residues K344 and R446, 
and K140 and R134, respectively (Figure 3.41). Based on the positioning of 
sulfates that co-crystalize with NT5C2, it seems reasonable that a nucleotide 
could bind to effector site 2 and has one or more phosphates coordinated by the 






It is hard to speculate as to the effect a bound ATP molecule would have 
on the disordered loop –pocket interaction as this first requires crystallization, or 
at least robust docking with ATP. Preliminary molecular docking with ATP on 
effector site 2 suggests that it is spatially and electrostatically feasible to add 
triphosphate onto the terminal ribose of 2JC9 adenosine.  Despite this, 
incubation with ATP, dATP, AP4A, BP3, GMP, dGMP in Walden et al.’s 2011 
study failed to achieve nucleotide binding at this site. Compounds that remain 
untested, or at least unpublished, include ADP, GDP, AMP, as well many other 
nucleoside variants(Cline, Smoot et al. 2007). The lack of binding in crystal 
structures suggests one of three possibilities: 1) Effector-site 2 is not a ligand 
binding site but instead acts as a pocket of interaction for other NT5C2 
regions (such as the C-terminal tail acidic stretch and loop that are missing), 2) 
Effector site 2 is a ligand binding pocket but the ligand has not been tested, or 3) 
Effector site 2 is a ligand binding pocket and has been incubated with 
physiologically relevant ligand but is unable to crystalize as such for unknown 
experimental reasons. Spatially, the DHE loop could not sit in several of its 
lowest energy conformations with Adenosine present. However, with two or even 
one (ATP and ADP respectively) terminal phosphates added to adenosine, the 
models would likely be altered significantly. It is possible that the DHE loop and 
effector site 2 ligand work competitively, but other possibilities cannot be ruled 
out without more concrete conformations. Understanding these interactions is 
important, as this regulatory site opens additional areas of an already existing 
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ligand binding site to development of inhibitors for therapeutic use. Currently, all 
developed NT5C2 inhibitors act competitively by mimicking nucleoside 
monophosphate structure and binding to the enzymes active site(Meurillon, 
Marton et al. 2014). As nucleosides, and enzymes that process them, are 
ubiquitous, these inhibitors run a strong risk of many off target effects and 
unforeseen toxicities (Petter Jordheim and Chaloin 2013). Allosteric inhibitors, 
however, hold the potential for specific NT5C2 inhibition. Furthermore, as the 
majority of NT5C2 activating mutations seem to affect this allosteric control site, it 
is plausible that inhibitors could be developed to be selective for hyperactive 
NT5C2, further reducing negative side effect profiles.  The only way to definitively 
address this and many aforementioned questions is through additional 
crystallization of the NT5C2 protein. However, collectively the work compiled in 
this thesis make significant strides into the understanding of NT5C2 regulation. 
This includes the description of a completely novel negative feedback 
mechanism that creates the first valid opportunity of feasible NT5C2 inhibitor 
development. (Figure 3.32).  
 
   
Conclusion 
While the number and variety of DNA variations across a given cohort of cancer 
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patients can be staggering, the prevailing notion maintains that the vast majority of 
alterations within tumor genomes are passenger or secondary in nature and only a 
small subset are responsible for driving tumorigenesis and metastatic disease. 
Identification of these alterations, called ‘drivers’, is held as the key to unlocking new 
therapeutic and diagnostic avenues in the future. In this thesis I have documented 
several strategies for identifying such alterations through use of next generation 
sequencing and post processing of NGS data. Here collaborators and I have 
accomplished the discovery of a mutation in the gene encoding the enzyme cytosolic 5-
nucleotidase II (NT5C2) in 19% of patients with relapsed T-ALL and 1 of 35 (3%) 
patients with relapsed B-ALL. These gain-of-function mutations were identified only in 
relapsed disease, and shown to convey resistance to 6-mercaptopurine and 6-
thioguanine, but not to nelarabine or ara-G (guanine arabinoside), two 
chemotherapeutic agents that are often used in T-ALL salvage regimens. Given the 
identification of NT5C2’s role in drug resistance to nucleoside analogue therapies and 
neurotoxicity in Lesch Nyhan and other neurological disorders, the need for an 
efficacious NT5C2 specific inhibitor has become increasingly apparent. Despite this, 
current inhibitor schemes lack true potential as they lack the ability to specifically target 
NT5C2 mutated proteins and thus prevent significant toxicity and unwanted side effects. 
In order to identify other potential avenues I have undertaken a deep investigation into 
the structural mechanism through which each mutation acts. The result of this in silico 
analysis is the discovery of a potential emergent allosteric regulatory mechanism never 
before described. Most notably, the majority of NT5C2 mutations identified have 
characteristics that suggest they abrogate the function of this proposed mechanism. 
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These findings not only create a viable target for allosteric inhibition free of the 
obstacles of substrate mimicking inhibitors, but also a site in which mutation specific 
inhibitors become a feasible prospect. Furthermore, as the majority of NT5C2 activating 
mutations seem to affect this allosteric control site in a similar fashion, it is plausible that 
a single inhibitor could be developed to address NT5C2 hyperactivity in a majority of 
patients (Table 3.3). Although this work provides logically sound findings heavily 
supported through robust in silico prediction, the only way to definitively address the 
specific workings of the NT5C2 DHE domain is through additional crystallization of the 
NT5C2 protein. This work has already commenced in the form of a significant 
collaboration between the laboratories of Adolfo Ferrando M.D. and Liang Tong Ph.D. to 
crystalize and describe the functional role of NT5C2 allosteric DHE mechanisms both in 
WT and mutated proteins. These future studies will provide the means to develop 
mutation specific NT5C2 inhibitors capable of addressing many relapsed patients with 









Materials and Methods 
 
Chapter 2 Methods 
Structural depiction and analysis. 
I identified structural coverage of the NT5C2 protein through use of the PSI-Blast and 
SKAN algorithms; we subsequently mapped viable structures to all NT5C2 isoforms and 
analyzed them using Chimera Suite(Pettersen, Goddard et al. 2004). We aligned 
structurally the PDB structures 2XCW, 2XCX, 2XCB, 2XCV, 2XJB, 2XJC, 2XJD, 2XJE, 
2XJF, 2J2C and 2JC9 and subsequently analyzed the composite structure to assess 
conformational flexibilities(Wallden and Nordlund 2011). We structurally modeled 
NT5C2 mutations using the I-TASSER software suite and subsequently refined and 
analyzed them by minimization and rotamer library analysis in Chimera(Roy, Kucukural 
et al. 2010). We predicted protein stability changes resulting from mutation through use 
of the SDM potential energy statistical algorithm and associated software(Worth, 
Preissner et al. 2011). We created all structural images using UCSF Chimera34. 
Patient samples. 
DNAs from leukemic T-ALL blasts at diagnosis and relapse and matched remission 
lymphocytes were provided by the Hemato-Oncology Laboratory at University of Padua, 
Italy; the Eastern Cooperative Oncology Tumor Bank Laboratory in New York, New 
York, USA; and the Department of Pediatric Oncology/Hematology at the Charité-
Universitätsmedizin Berlin in Berlin, Germany. Informed consent was obtained at study 
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entry. Samples were collected and analyzed under the supervision of the local 
Columbia University Medical Center Institutional Review Board. Selected samples for 
whole-exome sequencing were chosen on the basis of the availability of sufficient DNA 
from diagnosis, remission and relapse samples, and we evaluated high tumor content at 
relapse on the basis of copy number analysis of T cell receptor–associated deletions. 
Whole-exome capture and next generation sequence analysis. 
We matched diagnostic remission and relapsed DNA samples from five patients with T-
ALL from the University of Padua treated under Associazione Italiana Ematologia 
Oncologia Pediatrica (AIEOP) protocols for exome capture with the SureSelect 50 Mb 
All Exon kit (Agilent Technologies) following standard protocols. We performed paired-
end sequencing (2 × 100 bp) by using HiSeq2000 sequencing instruments at Centrillion 
Biosciences. Illumina HiSeq analysis produced between 60 million and 120 million 
paired-end reads per sample. We mapped reads to the reference genome hg19 using 
the Burrows-Wheeler Aligner (BWA) alignment tool version 0.5.9. The mean depth 
(defined as the mean number of reads covering the captured coding sequence of a 
haploid reference) was 50×, with 80% of the genome covered more than 10× and 57% 
covered more than 30×. We identified sites that differed from the reference (called here 
variants) in each sample independently. We constructed empirical priors for the 
distribution of variant frequencies for each sample. We obtained high-credibility intervals 
(posterior probability 1–10−5) for the corresponding change in frequency between 
tumor and normal samples using the SAVI (Statistical Algorithm for Variant 
Identification) algorithm developed at Columbia University(Trifonov, Pasqualucci et al. 
2013). The number of germline SNPs in the coding region was 18,000, which is 
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comparable with previous reports(Tiacci, Trifonov et al. 2011). Most of the candidate 
germline SNPs (16,000, or ~90% of germline variants) were reported in the dbSNP 
database. We identified candidate somatic variants using the following criteria: variant 
total depth in tumor and normal >10× and <300×, variant frequency >15% in tumor and 
<3% in normal and 1% change in frequency from the normal with high posterior 
probability (1–10−5). Also, to remove systematic errors, we excluded all variants that 
were found in unaffected individuals. In addition, to eliminate ambiguous mapping from 
captured pseudogenes and regions of low complexity, each variant with a flanking 20-
base context sequence around its genomic position was mapped to the hg19 reference 
using the BLAST algorithm. We kept in the list only those with unique mappability; that 
is, we required the 41-base sequence to uniquely map to the reference genome with 
only one mismatch. 
To discern the regions of loss of heterozygosity (LOH), SAVI-calculated high-credibility 
intervals for the variants in dbSNP were used, which correspond to the change in their 
frequency between tumor and normal samples. In an LOH event, depending on whether 
the reference or the dbSNP allele was lost, at least a 1% or at most a −1% change in 
frequency from the normal is expected. Therefore, by segmenting the regions covering 
more than ten dbSNP variants with significantly changed frequencies, we were able to 
identify the LOH regions. 
Mutation validation and analysis of recurrence. 
Ferrando lab collaborators designed primers flanking exons containing candidate 
somatic variants using Primer3 (http://frodo.wi.mit.edu/primer3/) and used them for PCR 
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amplification from whole genome–amplified (WGA) tumor, relapse and matched normal 
(remission) DNAs. We analyzed the resulting amplicons by direct bidirectional 
dideoxynucleotide sequencing with a validation rate of 97%. After exome sequence 
analysis of 5 diagnostic relapse and remission T-ALL AIEOP samples from the 
University of Padua (Supplementary Table 2.1), 18 additional patient samples from the 
same institution were used for the analysis of recurrence of TP53, BANP, RPL11, 
NRAS and NT5C2 (Supplementary Table 2.1). We subsequently extended this series to 
additional relapse T-ALL samples from the University of Padua (n = 13) and the Charité-
Universitätsmedizin Berlin (n = 67) (Supplementary Table 2.1) and to relapsed patients 
with B-precursor ALL from the University of Padua (n = 35) for extended mutation 
analysis of NT5C2 (Supplementary Table 2.1). We used two cohorts of diagnostic 
patients with T-ALL from ECOG (n = 23) and diagnostic patients with B-precursor ALL 
from the University of Padua (n = 27) to verify the absence of NT5C2 mutations in 
diagnostic ALL specimens (Supplementary Table 2.1). 
Site-directed mutagenesis. 
Ferando Lab collaborator Gannie Tzonvea generated the NT5C2 mutations K359Q, 
R367Q and D407A by site-directed mutagenesis on the mammalian expression pLOC-
NT5C2 vector (Open Biosystems) using the QuikChange II XL Site-Directed 
Mutagenesis Kit (Stratagene) according to the manufacturer's instructions. 
Cell lines. 
Gannie Tzonvea cultured CCRF-CEM and CUTLL1 cells in RPMI-1640 medium 
supplemented with 10% FBS, 100 U ml−1 penicillin G and 100 g ml−1 streptomycin at 


37 °C in a humidified atmosphere under 5% CO2. We maintained HEK293T cells under 
similar conditions in DMEM media. 
Lentiviral production and infection. 
Gannie Tzonvea transfected the lentiviral constructs pLOC-NT5C2, pLOC-NT5C2-359, 
pLOC-NT5C2-367 and pLOC-NT5C2-407 and the pLOC-RFP control plasmid with Gag-
Pol– and V-SVG–expressing vectors into HEK293T cells using JetPEI transfection 
reagent (Polyplus). We collected viral supernatants after 48 h and used them for 
infection of CCRF-CEM and CUTLL1 cells by spinoculation. After infection, cells were 
selected for 5 d in blasticidin and ficolled them the day before experiments. 
Western blot. 
Western blot analysis was performed using a rabbit polyclonal antibody to NT5C2 
(1:1,000, Abcam, ab96084) and a goat polyclonal antibody to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (1:1,000, Santa Cruz Biotechnology, sc-20357) 
using standard procedures. 
Cell viability and chemotherapy drug response. 
Gannie Tzonvea and Ariane Garcia determined cell viability by measurement of the 
metabolic reduction of the tetrazolium salt MTT using the Cell Proliferation Kit I (Roche) 
following the manufacturer's instructions. We performed experiments in triplicate. 
Viability was analyzed at 48 h or 72 h after initiation of treatment with 6-MP, 6-TG, 
nelarabine and AraG. 
Recombinant protein production and purification. 


Gannie Tzonvea and Arriane Garcia cloned full-length complementary DNA constructs 
encoding wild-type, K359Q, R367Q and D407A NT5C2 with an N-terminal hexahistidine 
(His6) tag in the pET28a-LIC expression vector using the In-Fusion HD PCR cloning 
system (Clontech) as per the manufacturer's instructions. Recombinant proteins were 
expressed from Rosetta 2(DE3) Escherichia coli cells by induction with 0.5 mM 
isopropyl--D-thiogalactopyranoside for 3 h at 37 °C. Cells were harvested and lysed 
them in lysis buffer (50 mM sodium phosphate, pH 7.4, 100 mM NaCl, 10% glycerol, 5 
mM -mercaptoethanol, 1% Triton X-100, 0.5 mg ml−1 lysozyme and 20 mM imidazole) 
supplemented with Complete EDTA-free protease inhibitor (Roche). His6-tagged 
NT5C2 proteins were purified by binding them to nickel-Sepharose beads and eluting 
them with 50 mM sodium phosphate, pH 7.4, 100 mM NaCl, 10% glycerol, 5 mM -
mercaptoethanol and 300 mM imidazole. Imidazole was removed by buffer exchange 
using PD-10 desalting columns (GE Healthcare) and protein expression and purity was 
assessed by SDS-PAGE and Coomassie staining. 
5-NT assay. 
Gannie Tzonvea and Arriane Garcia assessed 5-NT activity of purified recombinant 
wild-type and mutant NT5C2 proteins using the 5-NT Enzymatic Test Kit (Diazyme) 
according to the manufacturer's instructions. The assay measures the enzymatic 
hydrolysis of inosine 5-monophosphate to inosine, which is reacted further to 
hypoxanthine by purine nucleoside phosphorylase and then to uric acid and hydrogen 
peroxide by xanthine oxidase. H2O2 is quantified using a Trinder reaction.  5-NT 
activity levels were calculated using a calibrator of known 5-NT activity as standard and 




Gannie Tzonvea and Arriane Garcia evaluated differences in the percentages of wild-
type and mutant NT5C2 in patients with ALL in different relapsed categories using 
Fisher's exact test. The equality of categorical and continuous variables were analyzed  
by Fisher's exact test and Mann-Whitney U test, respectively. 
Chapter 3 Methods 
Figure Creation  
All structure figures were generated through use of the Chimera program 
suite(Pettersen, Goddard et al. 2004). 
Structural Homology Identification 
Structural coverage of the NT5C2 protein was identified through use of the PSI-
Blast and SKAN algorithms. Identified hits were subsequently mapped viable structures 
to all NT5C2 isoforms and analyzed them using Chimera Suite(Pettersen, Goddard et 
al. 2004).  
Protein Cavity Analysis  
Cavity Analysis was conducted through use of CAsTp Webserver and Chimera 
interface(Dundas, Ouyang et al. 2006). NT5C2 structure PDB files were re-written to 
contain quaternary structure coordinates. These files were subsequently used as input 
into the CaStP algorithm with a probe radius set at the default 1.4 Angstroms. HET 
groups were included in (Dundas, Ouyang et al. 2006)calculations that were set to 




Electrostatics of NT5C2 molecular surfaces were investigated with APBS and 
PDB2PQR software packages. PDB2PQR submission was run with a PARSE force 
field, optimal hydrogen bonding network. PROPKA was utilized to assign protonation 
states for each structure at their respective crystallization pH(Unni, Huang et al. 2011). 
molecular solvation programs through the Chimera Interface(Unni, Huang et al. 2011). 
Grid dimensions were set at 161, 161, and 193. Boundary condition for coarse grid was 
set by single Debye-Huckel. Solute dielectric constant (pdie) set to 2.0 and solvent 
dielectric constant (side) set to 78.54. Charge mapping method utilized was cubic B-
spline discretization. Mobile ions were not included and Poisson-Boltzmann was run 
with linearized (lpbe) setting. Surface density of 10.0 and solvent radius of 1.4 were 
used. System temperature set to 298.15 with explicit solvent not included. 
Supplementary electrostatics analysis and visualization was conducted through use of 
the Columbic surface coloring algorithm provided in Chimera software 
package(Pettersen, Goddard et al. 2004).  
Structural Modeling 
All modeling was conducted through use of Modeller and I-TASSER webserver(Eswar, 
Eramian et al. 2008, Roy, Kucukural et al. 2010). Loop models were built, refined and 
scored through use of Modeller Software suite(Fiser, Do et al. 2000, Eswar, Eramian et 
al. 2008). Top models for figures were selected by ranking 5000 iterations by DOPE 
score (see below ‘model_energies_script) as described elsewhere(Fiser, Do et al. 
2000). Refinement parameters were set to loop refine slow to ensure highest quality 


models possible. Models were refined repeatedly through use of Modeller software and 
Chimera based plug-ins. 
Secondary Structure prediction. 
All secondary structure prediction was conducted through use of the predict protein 
platform and webserver(Rost, Yachdav et al. 2004).  
Protein Stability Assessments 
Protein stability changes upon mutation were assessed through use of the SDM 
potential energy algorithm and webserver on re-written biological unit tetrameric NT5C2 
structure PDBs(Worth, Preissner et al. 2011). In-silico mutagenesis was conducted with 
Modeller Software suite utilizing SDM output as starting template structure(Eswar, 
Webb et al. 2006, Eswar, Eramian et al. 2008).  
Structure Morphing  
Path prediction and molecular dynamics of NT5C2 models was predicted thorugh 
use of UCSF Chimera tools and software(Pettersen, Goddard et al. 2004). Minimization 
of mutants was conducted using a 6-angstrom sphere to specify fixed and unfixed 
atoms, 1000 steepest descent steps, steepest descent step size of .02 angstroms, 100 
conjugant gradient steps of .02 angstroms each. Residues with one or more atoms 
included in sphere were included in their entirety regardless of full inclusion in 
6Angtroms from any point of mutant residue. Hydrogen bonding networks and Vander 
wall clashing predicted through use of UCSF Chimera Software(Pettersen, Goddard et 
al. 2004).  
	

Sequence Alignments and Homology Assessments  
All multiple sequence alignments and figures were created with CLC Bio Software and 
methods(Workbench 2009). Motif scanning analysis was conducted with ExPasy prosite 
webserver(Artimo, Jonnalagedda et al. 2012). Docking, ligand screening, and 
supplementary cavity analysis was conducted through CLC drug discovery 
workbench(Workbench 2009). 
PDB files 
All protein sturctures for NT5C2 were obtained from the PDB repository. PDB IDs 
2XCW, 2XCX, 2XCB, 2XCV, 2XJB, 2XJC, 2XJD, 2XJE, 2XJF, 2J2C and 2JC9 . All PDB 













































































































































































































































































































































































































































































































































































































































Appendix A. Further Unraveling the genetics of T-ALL 
During Relapse 
A Summary 
Although multi-agent combination chemotherapy is curative in a significant fraction of 
acute lymphoblastic leukemia (ALL) patients, 20% of cases relapse and most die due to 
chemo-refractory disease. Here we used whole-exome sequencing to analyze the 
mutational landscape and pattern of clonal evolution at relapse in 57 pediatric ALL 
cases. These analyses showed that ALL relapses originate from a common ancestral 
precursor clone of the diagnosis and relapsed populations and frequently harbor 
mutations implicated in chemotherapy resistance (NT5C2, CREBBP, NR3C1, TP53). 
Notably, RAS-MAPK activating mutations in NRAS, KRAS and PTPN11 were present in 
21/57 (37%) cases in our series and oncogenic KRAS (KRAS G12D) conferred 
resistance to chemotherapy with methotrexate when expressed in ALL lymphoblasts. 
These results identify chemotherapy driven clonal selection and branched clonal 
evolution as mechanisms of leukemia progression and relapse and implicate, for the 
first time, the RAS-MAPK pathway as a driver of methotrexate resistance in ALL. 
Our sequencing analysis yielded an average of 9 mutations at diagnosis and 17 
mutations at relapse through a mean coverage depth of 89.4x per exome with 82.5% of 


targeted regions covered at frequencies higher than 30x. Figure 4.1 displays the 
breakdown of mutations between sample type for most recurrent genes. 
Altogether, 1,079 genes were affected by mutations of which 94 appeared recurrently in 
at least 2 cases while 24 showed reccurency in three or more patients . Somatically 
mutated genes in our series included known oncogenes and tumor suppressors 


recurrently mutated in B-precursor leukemias (KRAS, NRAS, FLT3, JAK2, JAK3, and 
CREBBP) 17 and T-ALL (NOTCH1, FBXW7, PHF6, DNM2, WT1, JAK1, JAK3, 
BCL11B, TP53, CREBBP, RPL10, RUNX1, CNOT3 and MAGEC3) in addition to 
numerous new genes not previously implicated in the pathogenesis of this disease 
(Figure 4.2) 18-25. 
 
 
Analysis of mutations acquired at the time of relapse identified 28 genes harboring 
recurrent mutations gained during disease progression (Figure 4.1). Amongst the 
mutations, heterozygous, relapse-specific mutations in the NT5C2 gene were identified 


in 10/57 (17%) cases [1/24 (4%) in B-precursor ALL; 9/33 (27%) in T-ALL]. These 
included, three previously characterized gain of function NT5C2 alleles (NT5C2 R238W, 
NT5C2 K359Q and NT5C2 R367Q) involved in 6-MP and 6-TG resistance 13,14, two 
mutations at positions altered in previously reported NT5C2 gain of function alleles 
(NT5C2 D407E, NT5C2 S445F R446Q) and one novel NT5C2 mutation (NT5C2 
R478S) (Figure 4.2). As in the case of previously characterized relapse-associated 
NT5C2 mutations, expression of the new NT5C2 R478S allele was shown by 
collaborators to induce increased resistance to chemotherapy with 6-mercaptopurine 
and 6-thioguanine . 


Moreover, and consistent with the prominent role of glucocorticoids in the treatment of 
ALL, we identified two cases with relapsed-acquired mutations in the glucocorticoid 
receptor gene (NR3C1) (Figure 4.1). Mutations were also identified in CREBBP, a gene 
encoding a histone acetyl-transferase involved in glucocorticoid induced transcriptional 
regulation, in 4 cases [4/57 (7%); 2/24 (8%) B-precursor ALLs; 2/33 (6%) T-ALLs] 
including 3 patients with mutations acquired at the time of relapse (Figure 4.1, Figure 
4.2) Consistent with the proposed role for loss of CREBBP activity in relapsed ALL 
23,30, CREBBP mutations in our series included truncating mutations (CREBBP 
	

Q1803* and CREBBP E1709*) and single amino-acid substitutions in the histone acetyl-
transferase domain (CREBBP P1488L and CREBBP Y1450C) (Figure 4.2). Further 
analysis of relapse-associated mutations in our series revealed 4/57 (7%) mutations in 
the MLL2 H3K4 histone methyl-transferase gene, 3 of which were acquired at relapse. 
In addition, we identified 4 T-ALLs with mutations in the TP53 gene (4/33, 13%), a major 
mediator of radiation and chemotherapy induced apoptosis 31,32, one of which was 
specifically acquired at the time of relapse (Figure 4.1, 4.2).  
In this scenario, it was hypothesized that driver genes mutated in relapsed ALL 
could be functionally related in their effector pathways. Moreover this suggested that 
analysis of protein- protein interactions in the space of relapse-associated mutations 
could reveal critical mechanistic nodes involved in chemotherapy resistance. To test this 
hypothesis, I analyzed experimentally established protein-protein binding interactions 
across 153 genes harboring at least one mutation gained at relapse in our series. This 
analysis revealed a network structure in which most interactions converged on a limited 
number of highly connected proteins (Figure 4.3). Notably, the highest connected 
nodes in this circuitry encompassed the products of key genes whose mutations can 
drive chemotherapy resistance (TP53, CREBBP and NR3C1) (Figure 3.3). The protein-
protein binding networks formed by each of these proteins further highlights the linkage 





Next, in-order to test for potential roles for the linked genes with chemotherapy 
resistance, I analyzed their intersection with documented metabolic pathways of T-ALL 
therapies(Knox, Law et al. 2011). The most striking findings of this analysis were 9 
unique gene hits to PharmGKB purine metabolism pathway and 6 unique gene hits to 




In addition, several other metabolic pathways featured genes with mutations in our 
series. To assess whether or not any of these genes might play a driving role behind 
resistance to particular drugs, I clustered our mutation data by gene, sample, and drug 
pathway. Strikingly, almost no overlap between drug-associated genes was observed 




Collectively these findings identify several novel genes involved in drug resistance of T-







Appendix B. Reverse engineering of oncogenic 
transcriptional networks in T-cell leukemia 
 
Summary  
The TLX1 and TLX3 transcription factor oncogenes play an important role in the 
pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL)(Ferrando, Neuberg et al. 
2002, Aifantis, Raetz et al. 2008). Here reverse engineering of global transcriptional 
networks was utilized to decipher the oncogenic regulatory circuit controlled by TLX1 
and TLX3. This Systems Biology analysis defined TLX1 and TLX3 as master regulators 
of an oncogenic transcriptional circuit governing T-ALL. Notably, network structure 
analysis of this hierarchical network identified RUNX1 as an important mediator of TLX1 
and TLX3 induced T-ALL. Through structural informatics methods, RUNX1 mutations 
were predicted to have a tumor suppressing in T-cell transformation. Mapping of TALL 
RUNX1 mutations on the structure of the RUNX1 runt domain (PDB 1H9D) showed 
clustering of these amino acid substitutions in the DNA recognition interface of RUNX1 
(Figure 5.1). Most strikingly, the RUNX1 H78 residue resides within a highly structurally 
conserved 16.9 Å diameter cavity frequently targeted by RUNX1 AML mutant alleles, 
which is adjacent to the DNA binding interface and is predicted to be disrupted in the 
RUNX1 H78Y T-ALL mutant. Consistent with these results, we identified recurrent 
somatic mutations in RUNX1 that occur in the DNA binding domain of the protein 
structure in human T-ALL primary patient samples and cell lines (Figure 5.1c). Next we 




disruptive in luciferase reporter assays. In these experiments, the RUNX1 H78Y, 
RUNX1 S114fs and RUNX1 G138fs mutants showed marked (80%) reductions in their 
capacity to activate a RUNX1-responsive colony-stimulating factor (CSF) promoter 
reporter construct compared to wild-type RUNX1 (Fig. 5.1d). 
 
Overall, these results place TLX1 and TLX3 atop of an oncogenic transcriptional 
network controlling leukemia development, demonstrate power of network analysis to 
identify key elements in the regulatory circuits governing human cancer and identify 





Appendix C. Genetic Landscape of Peripheral T-Cell 
Lymphoma  
Summary  
Peripheral T cell lymphomas (PTCLs) are a heterogeneous and poorly understood 
group of non-Hodgkin lymphomas1, 2. Here whole-exome sequencing of 12 tumor-
normal DNA pairs, RNA sequencing analysis and targeted deep sequencing  were 
combined to identify new genetic alterations in PTCL transformation. These analyses 
identified highly recurrent epigenetic factor mutations in TET2, DNMT3A and IDH2 as 
well as a new highly prevalent RHOA mutation encoding a p.Gly17Val alteration present 
in 22 of 35 (67%) angioimmunoblastic T cell lymphoma (AITL) samples and in 8 of 44 
(18%) PTCL, not otherwise specified (PTCL-NOS) samples. Mechanistically, the RHOA 
Gly17Val protein interferes with RHOA signaling in biochemical and cellular assays, an 
effect potentially mediated by the sequestration of activated guanine-exchange factor 
(GEF) proteins. In addition, we describe new and recurrent, albeit less frequent, genetic 
defects including mutations in ATM, B2M and CD58 implicating SRC signaling, impaired 
DNA damage response and escape from immune surveillance mechanisms in the 
pathogenesis of PTCL. In addition, we detected the presence of new recurrent FYN 
kinase (NM_002037) mutations, including a recurrent allele encoding a p.Arg176Cys 
substitution present in two PTCL-NOS cases and a mutation encoding a p.Leu174Arg 
alteration found in one AITL sample, in addition to the p.Tyr531His-encod- ing allele 
identified via exome analysis in a PTCL-NOS sample, for an overall frequency of 3% 
(4/137) for FYN mutations in our series (Fig. 6.1). The FYN tyrosine kinase is, along 
	

with LCK, the predominant SRC family kinase found in T lymphocytes and has an 
important role in T cell activation upon T cell receptor (TCR) stimulation. 
Strikingly, FYN mutations found in PTCL are predicted to specifically disrupt the 
intramolecular inhibitory interaction of the FYN SH2 domain with the C-terminal SRC 
kinase (CSK)-phosphorylated Tyr531 residue. Consistently, expression of FYN 
Leu174Arg, FYN Arg176Cys and FYN Tyr531His in Rat1A rat embryo fibroblast cells 
resulted in increased levels of FYN activation compared with control cells expressing 
wild-type FYN (Fig. 4.2a,b). In addition, structural model analysis of wild-type and 
mutant FYN proteins further supported this hypothesis (Fig. 6.2c,d). To test this model, 
we analyzed the interaction between recombinant GST-fused FYN SH2 domain and 
biotinylated C-terminal FYN peptides encompassing position Tyr531. In these assays, 
wild-type FYN SH2 domain was effectively pulled down with the phosphopeptide with 
Tyr531 phosphorylated but not with the corresponding unphosphorylated sequence or 
with a peptide contain- ing a p.Tyr531His substitution (Fig. 6.2e). Similarly, the 
introduction of a p.Leu174Arg or a p.Arg176Cys substitution abrogated the interaction of 
FYN SH2 domain with the C-terminal FYN peptide phoshorylated at Tyr531 (Fig. 6.2f). 
Consistently, CSK effectively inhibited wild-type FYN but did not abrogate the activity of 
	

the mutant FYN proteins (Fig. 6.2g). Finally, given the prominent role of kinase 
inhibitors as targeted ther- apies for tumors driven by constitutively active kinase 
oncogenes, we tested the ability of dasatinib, a multikinase inhibitor that blocks ABL1 
and SRC kinases, to inhibit the activity of FYN Leu174Arg, FYN Arg176Cys and FYN 
Tyr531His mutant proteins. Notably, in each case, dasatinib treatment induced dose-
dependent inhibition of FYN phosphorylation (Fig. 6.2h). Moreover, dasatinib treatment 
impaired the growth of transformed Rat1A cells expressing the FYN Tyr531His mutant 
protein but not that of cells expressing a drug- resistant gatekeeper mutant of this 
kinase (FYN Thr342Ile/Tyr531His) (Fig. 6.2i,j). On the basis of these results, we 
	

propose that SRC kinase inhibition with dasatinib may confer therapeutic benefit in 























































AA.D Methods  
Appendix A 
Patient samples. DNAs from leukemic ALL blasts at diagnosis and relapse and 
matched remission lymphocytes were provided by the Children’s Oncology Group; the 
Pediatric Oncology Division at Columbia University Medical Center; the Department of 
Hematology/Oncology, Saitama Children’s Medical Center, Saitama, Japan; and the 
Hemato-Oncology Laboratory at University of Padova, Italy. Informed consent was 
obtained at study entry. We collected and analyzed samples under the supervision of 
the local Columbia University Medical Center Institutional Review Board. Collaborators 
selected samples for whole exome sequencing on the basis of the availability of 
sufficient DNA from diagnosis, remission and relapse samples. Sample size was 
determined to have 95 % power to detect recurrent mutations present in over 5% of 
samples and 78% power to detect these as recurrent in at least two samples. 
Extraction of genomic DNA 
Genomic DNA was extracted from patient leukemic blasts or from the lymphoid fraction 
from peripheral blood at remission using the Qiagen DNeasy Blood & Tissue Kit. 
Whole exome capture and next generation sequencing. We used purified high 




relapse samples of 57 ALL patients. The DNA sequences were enriched in protein-
coding sequences by using the Agilent SureSelect Human 51Mb All Exon V4 kit (Agilent 
Technologies), and amplified and subjected to high-throughput paired-end (2 × 100 bp) 
sequencing on the Illumina HiSeq2000 System at Centrillion Biosciences, Inc. The 
analysis produced an average of 90.1 million paired- end reads per sample. After 
filtering for duplicate reads (i.e. reads with identical start and orientation), sequences 
were aligned to the reference human genome hg19 assembly using the Burrows-
Wheeler Aligner (BWA) tool version 0.5.9 39. In average 98.4% mapped properly to 
human genome (Supplementary Table1). We independently obtained sequence 
variants (nucleotide substitutions and small deletions and insertions) for tumor and 
remission samples. We used the SAVI (Statistical Algorithm for Variant Identification) 
algorithm 16, which constructed empirical priors for the distribution of variant 
frequencies in each sample. From that prior, we obtained a corresponding high-
credibility interval (posterior probability 1–10−5) for the frequency of each variant and a 
high-credibility interval for the corresponding change in frequency between the 
diagnosis or relapse tumors and normal samples or the relapse vs. diagnosis samples. 
Variants were considered absent when observed with a frequency of 0 to 2%, and 
present when observed with a frequency 3%. We chose 3% as the lower threshold for 
detecting variants, considering our mean depth of coverage of >80x across samples, 
and errors occurring with a rate of 1% for the technology, following a binomial 
distribution. Mutations were classified as clonal if the fraction of variant reads was 
15%. Variants were then filtered for i) systematic errors known to be associated with 




variants mapping to multiple loci in the genome, which may reflect captured 
pseudogenes and regions of low complexity. To this end, each variant with a flanking 
35-base context sequence around its genomic position was mapped to the hg19 
reference using the BLAST algorithm, and only variants with “unique mappability” were 
retained, that is, we required the 71-base sequence to uniquely map to the reference 
genome with only one mismatch. The average number of germline SNP variants per 
sample obtained by sequencing was 20,000, 90% of which were reported in the dbSNP 
database, comparable to the numbers of SNPs detected in previous reports 40. 
Identification of somatic variants (SVs). Candidate somatic variants were obtained by 
excluding i) variants present in the corresponding paired remission DNA, ii) variants 
present in any one of 220 exomes from unaffected individuals that were analyzed at our 
institution. Relapse-specific somatic variants were defined as those clonally represented 
in relapse and absent in diagnosis. We similarly defined diagnosis-specific somatic 
variants. Shared somatic variants were defined as those present in both relapse and 
diagnosis, but clonally represented in at least one sample. Circular representation of 
recurrence of diagnostic-specific and relapse – specific genetic alterations in recurrently 
mutated (3 lesions) genes was generated using Circos software 41. 
  PPI Protein-protein physical binding networks were generated by crossing all genes 
with somatic mutations at relapse with the BIO-Grid Homo sapiens specific database 
using in-house developed software and methods(Stark, Breitkreutz et al. 2006). Protein 
specific networks were generated as a subset of the global relapse binding network with 




protein of interest. All network figures and legends were generated through use of 
Cytoscape 3 software(Cline, Smoot et al. 2007). 
  
Drug Analysis.  Drug pathway analysis was accomplished by crossing filtered 
sequencing results with drug annotation databases SMPDB and DrugBank(Frolkis, 
Knox et al. 2010, Knox, Law et al. 2011). All standard and relapse specific therapies 
(uptodate) as well as therapies with close chemical structure to these regimens were 
included in this analysis (Frolkis, Knox et al. 2010, Knox, Law et al. 2011).Therapy 
pathway figures were created using DrugBank diagrams, and altered accordingly with 
Adobe Illustrator to show mutational impact 49. 
Appendix B Methods 
Structural depiction and analysis. 
Structural coverage of the RUNX1 protein was identified through use of the PSI-Blast 
and SKAN algorithms; viable structures were subsequently mapped to all RUNX1 
isoforms and analyzed with the MarkUS web annotation server29. The Protein Data 
Base structures 1EAN, 1EAO, 1EAQ, 1H9D, 1IO4, 1HJB, 1HJC and 2J6W were 
structurally aligned along the RUNX1 runt domain–DNA interface, and the resulting 
composite structure was subsequently analyzed to assess conformational flexibilities30. 
Potential effects for the RUNX1 mutants in T-ALL were investigated with SCREEN and 
VASP for cavity prediction and volumetric rendering, ConSurf for analysis of structural 
conservation, PredUS for protein-protein interface prediction and DelPhi to highlight 
potential alterations in electrostatic potential29. A probabilistic classification of mutations 





the use of the PolyPhen-2 batch servers and algorithms31. RUNX1 mutants in AML 
were extracted from the COSMIC database, filtered and mapped to runt domain 
structures30. All structural images were created using UCSF Chimera30. 
ChIP and ChIP-chip analysis. 
A ChIP-chip analysis of the TLX3 and RUNX1 target genes was performed in the HPB-
ALL cell line. Briefly, 1 × 108 cells were used for ChIP using A-17 goat polyclonal (sc-
23397) and H-55 rabbit polyclonal (sc-30185) antibodies to TLX3 (Santa Cruz 
Biotechnology) or two rabbit polyclonal antibodies to RUNX1 (Ab980 from Abcam and 
4336S from Cell Signaling Technologies). ChIP-chip was performed following the 
standard protocols provided by Agilent Technologies using Agilent Human Proximal 
Promoter Microarrays (244,000 features per array), as previously described28. This 
platform analyzes ~17,000 of the best-defined human genes sourced from UCSC hg18 
(NCBI Build 36.1, March 2006) and covers regions ranging from −5.5 kb upstream to 
+2.5 kb downstream of their transcriptional start sites. We scanned the arrays with an 
Agilent scanner and extracted the data using Feature Extraction 8 software. Genes that 
were direct targets of TLX3 and RUNX1 were identified using a ChIP-chip significance 
analysis, as previously described28. A ChIP-chip analysis of MYC and TLX1 in T-ALL 
has been previously reported11, 28. 
Relative real-time PCR quantification of the RUNX1 promoter sequences was 
normalized to the ACTB gene in chromatin immunoprecipitates performed with 
antibodies to TLX1 (C-18 rabbit polyclonal antibody (sc-880), Santa Cruz 
Biotechnology) and TLX3 (A-17 goat polyclonal antibody (sc-23397), Santa Cruz 




Appendix C Methods 
Patient samples. 
DNA samples from PTCLs were provided by tumor banks at the Columbia University 
Medical Center (New York, New York, USA), the Sylvester Comprehensive Cancer 
Center (Miami, Florida, USA), the Hospital Central de Asturias (Oviedo, Spain), the 
Centro Nacional de Investigaciones Oncologicas (Madrid, Spain), the Institut Gustave 
Roussy (Villejuif, France), the Centre Henri Becquerel (Rouen, France) and Hospital 
Clinic (Barcelona, Spain). Samples were obtained with informed consent, and analysis 
was conducted under the supervision of the Columbia University Medical Center 
Institutional Review Board. We selected samples for whole-exome sequencing on the 
basis of the availability of sufficient DNA from diagnosis and normal (blood, buccal swab 
or non-tumor infiltrated biopsy material) matched samples. 
Whole-exome capture and next-generation sequence analysis. 
We used matched tumor and normal DNA samples from 12 individuals with PTCL 
(Supplementary Table 1) for exome capture with the SureSelect 50Mb All Exon kit 
(Agilent Technologies), following standard protocols. We performed paired-end 
sequencing (2 × 100 bp) using HiSeq 2000 sequencing instruments at Centrillion 
Biosciences (Palo Alto, California, USA). Illumina HiSeq analysis produced between 
67.5 and 136.8 million paired-end reads per sample (Supplementary Table 2). We 
mapped reads to the hg19 reference genome using the Burrows-Wheeler Aligner 
(BWA) alignment tool version 0.5.9. Mean depth (defined as the mean number of reads 




the genome covered by more than 10× and 58% of the genome covered by more than 
30×. We identified sites that differed from the reference (called here variants) in each 
sample independently. We constructed empirical priors for the distribution of variant 
frequencies for each sample. We obtained high-credibility intervals (posterior probability 
 1–10−5) for the corresponding change in frequency between tumor and normal 
samples, using the SAVI algorithm (Statistical Algorithm for Variant Identification) 
developed at Columbia University20, 21. There were 18,000 germline SNPs in the 
coding region, comparable to the numbers of SNPs detected in previous reports20. 
Most of the candidate germline SNPs (16,000 or ~90% of germline variants) were 
reported in the dbSNP database. We identified candidate somatic variants using the 
following criteria: variant total depth in tumor and normal greater than 10× and less than 
300×, variant frequency greater than 15% in tumor samples and less than 3% in normal 
samples, and at least 1% change in frequency from normal samples with high posterior 
probability (1–10−5). To remove systematic errors, we excluded all variants that were 
found to be present in any of the normal samples. In addition, to eliminate ambiguous 
mapping from captured pseudogenes and regions of low complexity, each variant with a 
flanking 20-base context sequence around its genomic position was mapped to the 
hg19 reference genome using the BLAST algorithm. We retained only the variants with 
unique mappability, i.e., we required the 41-base sequence to uniquely map to the 
reference genome, with only one mismatch. 
Mutation validation. 
We designed primers flanking exons containing 121 randomly selected candidate 




genome–amplified DNA from tumor and matched normal DNA samples for PCR 
amplification. We analyzed the resulting amplicons by direct bidirectional 
dideoxynucleotide sequencing and obtained a validation rate of 90% (Supplementary 
Table 1). 
RNA sequencing and mapping and identification of variants. 
After exome sequence analysis of 12 tumor and normal PTCL samples (Supplementary 
Table 1), we analyzed 34 additional PTCL samples by RNA-seq using paired-end 
Illumina HiSeq sequencing (Supplementary Table 7). We obtained on average over 
67.6 million reads, 51.5 million (75.7%) of which mapped to the human NCBI reference 
sequence (RefSeq) database using BWA alignment algorithms22. Reads mapping to 
the same starting position were discarded. We identified sites that differed from the 
reference in each sample and constructed empirical priors for the distribution of variant 
frequencies for each sample independently. To reduce the false positive rate in variant 
detection and remove mapping artifacts and systematic errors, we mapped paired-end 
reads for the samples to human RefSeq with the Bowtie 2 alignment algorithm23, which 
mapped a total of 1.83 billion reads (76%) properly to the reference. We then identified 
sites that differed from the reference in each sample and intersected the set of variants 
identified with both BWA and Bowtie 2 alignment as previously described24. In all 
samples, we selected variants with total depth of >10× and frequency of >20% and 
excluded variants identified in the dbSNP135 database, as well as those that did not 
pass the Multiplicity filter. In addition, variants corresponding to poorly expressed (< 3 
reads per kilobase per million) genes were removed to reduce the effects of spurious 




mutations, identified variants that were also present in 65 DNA sequencing samples 
from unaffected individuals were excluded, and we also removed variants common to 
those present in 11 RNA-seq samples from normal B and T cells. In detail, we mapped 
normal RNA-seq sample reads with BWA and Bowtie 2 to human RefSeq and identified 
variants, creating an internal normal variant database (INVD) composed of the union of 
all the variants identified in normal B and T cells. Successively, we filtered out variants 
occurring in PTCL samples that overlapped with the INVD variants. Finally, we limited 
the list of variants to those identified in genes found to be somatically mutated in PTCL 
by exome sequencing. 
Targeted deep resequencing. 
Mutational analysis of selected genes of interest was performed by targeted 
resequencing using microfluidics PCR (Access Array system, Fluidigm) followed by 
sequencing of the amplicon libraries on a MiSeq instrument (Illumina). Primers targeting 
the regions of interest were designed at Fluidigm to produce amplicons of 200 ± 20 bp. 
We performed multiplex PCR amplification of up to ten amplicons per well of the 
Fluidigm Access Array chip according to the manufacturer's instructions, using 30 ng of 
DNA per sample. After multiplex PCR amplification, resulting DNA products were 
barcoded so that all amplicons corresponding to each sample carried the same index. 
Indexed libraries were pooled, and the resulting library was quantified by quantitative 
PCR using the Kapa Library Quantification kit (Kapa Biosystems) on a 7500 PCR 
instrument (Applied Biosystems). Amplicon libraries were spiked with ~25% PhiX 
genomic library to increase amplicon diversity and were sequenced on a MiSeq 
instrument to generate 2 × 251-bp paired reads, following an amplicon sequencing 


protocol for custom primers. Each pair of paired-end reads produced by MiSeq was 
stitched together using FLASH version 1.2.6 (Fast Length Adjustment of SHort reads), 
given that the amplicon sequences (up to 200 bp) were shorter than the read length 
(251 bp). This step increased the quality of the reads, correcting for mismatches in 
overlap by selecting the base with higher quality. Then, 5 and 3 adaptors and PCR 
primer sequences were trimmed using cutadapt. Merged and trimmed reads were 
aligned to the UCSC hg19 reference genome as single-end reads using BWA-MEM. 
Aligned reads were analyzed for variants using the SAVI algorithm, and variants were 
selected on the basis of coverage depth and frequency. Given the presence of 
abundant normal cells in most PTCL samples, variants with a frequency of around 50% 
were flagged as candidate private germline SNPs. Candidate variants identified by this 
first round of amplicon resequencing were independently validated in a second round of 
targeted deep sequencing. Briefly, we selectively amplified the amplicons covering the 
positions of candidate mutations in their corresponding positive samples, barcoded 
these PCR products, pooled them and sequenced the resulting library on a MiSeq 
instrument. 
Structural depiction and analysis. 
We identified structural coverage of the FYN protein through use of the PSI-Blast and 
SKAN algorithms. The structures 2DQ7, 2DLY, 3UA7, 2LP5 and 1G83 were structurally 
aligned into composite structures to assess conformational flexibilities and subsequently 
analyzed through use of the Chimera Suite27, 28. In silico modeling of identified 
mutations was performed using the I-TASSER software suite and Modeller program; 
structures were refined and analyzed in Chimera27, 29. We predicted protein stability 


changes upon mutation through use of the SDM potential energy statistical algorithm 
and associated software30. We created all structural images using UCSF Chimera27. 
Plasmids and vectors. 
We obtained pcDNA3 EGFP-RHOA WT (plasmid 12965) containing the full-length 
human RHOA construct fused to EGFP as well as pcDNA3 EGFP–RHOA Thr19Asn 
dominant negative (plasmid 12967) and pcDNA3-EGFP–RHOA Gln63Leu constitutively 
active (plasmid 12968) mutants from Addgene31. We generated the RHOA allele 
encoding p.Gly17Val by site-directed mutagenesis on the mammalian expression vector 
pcDNA3-EGFP–RHOA WT using the QuikChange II XL Site-Directed Mutagenesis kit 
(Stratagene) according to the manufacturer's instructions. We cloned PCR products 
encompassing wild-type RHOA and encoding RHOA p.Gly17Val, RHOA p.Thr19Asn 
and RHOA p.Gln63Leu with an N-terminal HA tag as BglII-XhoI fragments into the 
pMSCV vector for retroviral expression. We obtained pRK5–c-FYN plasmid containing a 
full-length FYN ORF32 from Addgene (plasmid 16032), subcloned the FYN ORF in the 
pcDNA3.1 plasmid vector and introduced the mutations in FYN encoding FYN 
p.Leu174Arg, FYN p.Arg176Cys, FYN p.Tyr531His and FYN p.Thr342Ile/Tyr531His 
using the QuikChange II XL Site-Directed Mutagenesis kit. All constructs were verified 
by sequencing. Wild-type and mutant FYN cDNA encoding an N-terminal HA tag was 
subcloned into pcDNA3.1(−) and inserted into the MSCV240-puromycine-IRES-GFP 
retroviral vector. The CSK-pcDNA3.1 (+) hygro plasmid containing a full-length CSK 
ORF was a gift from X.-Y. Huang (Cornell University). We cloned FYN SH2 domain 
complementary DNA constructs encoding wild-type FYN SH2 domain (codons 148–
231) with an N-terminal GST tag in the pGEX4-T1 expression vector between the EcoRI 

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and XhoI restriction sites. We generated the FYN SH2 domain mutations encoding 
p.Leu174Arg and p.Arg176Cys by site-directed mutagenesis on the Escherichia coli 
expression pGEX4-T1 vector encoding the FYN SH2 domain using the QuikChange II 
XL Site-Directed Mutagenesis kit according to the manufacturer's instructions. 
Cell lines. 
We cultured HEK293T (Thermo Scientific), HeLa (American Type Culture Collection, 
ATCC) and Rat1A cells (a gift from A. Lasorella, Columbia University) in DMEM 
supplemented with 10% FBS, 100 U/ml penicillin G and 100 g/ml streptomycin at 37 
°C in a humidified atmosphere under 5% CO2. We maintained Jurkat cells (ATCC) 
under similar conditions in RPMI 1640 supplemented with 10% FBS. Cell lines were 
regularly tested for mycoplasma contamination. 
Retrovirus production and infection. 
We transfected the retroviral constructs pMSCV-HA-RHOA, pMSCV-HA–RHOA 
Gly17Val, pMSCV-HA–RHOA Gln63Leu, pMSCV-HA–RHOA Thr19Asn, pMSCV-FYN, 
pMSCV–FYN Tyr531His, pMSCV–FYN Thr342Ile/Tyr531His, pMSCV–FYN Arg176Cys, 
pMSCV–FYN Leu174Arg and the pMSCV control plasmid with gag-pol– and V-SVG–
expressing vectors into HEK293T cells using JetPEI transfection reagent (Polyplus). We 
collected viral supernatants after 48 h and used them for infection of Rat1A and Jurkat 
cells by spinoculation. After infection, we selected cells for 4 d in medium containing 1 
g/ml puromycin. 
Immunoprecipitation and protein blot analysis of FYN activation. 


We performed FYN immunoprecipitations in Rat1A cells infected with control (empty 
vector) retroviruses or with retroviruses expressing wild-type FYN, FYN Leu174Arg, 
FYN Arg176Cys or FYN Tyr531His using FYN rabbit polyclonal antibody (4023, Cell 
Signaling Technology)33 at 1:100 dilution and analyzed FYN phosphorylation via 
protein blot analysis with a Phospho-Src Family (Tyr416) polyclonal antibody (2101, Cell 
Signaling Technology) at 1:100 dilution. 
FYN protein expression in E. coli, purification, and peptide binding assays. 
We expressed wild-type and mutant FYN SH2 domain as GST-fused proteins in E. coli 
Rosetta 2(DE3) cells as detailed for the production of GST-RHOA fusion proteins. Next, 
we performed peptide binding assays with the Pull-Down Biotinylated Protein-protein 
Interaction kit (Thermo Scientific), according to the manufacturer's instructions, using a 
biotinylated FYN peptide corresponding to amino acids 527–537 (biotin-
TEPQYQPGENL), a biotinylated FYN peptide corresponding to amino acids 527–537 
with phosphorylation at Tyr531 (biotin-TEPQpYQPGENL) and a biotinylated FYN 
peptide corresponding to amino acids 527–537 with a p.Tyr51His alteration (biotin-
TEPQHQPGENL) (Anaspec). Briefly, we incubated synthetic biotinylated peptides with 
purified GST-fused FYN SH2 domain or mutant FYN SH2 domain or with GST alone for 
1 h at 4 °C, resolved and analyzed interacting proteins via 10% SDS-PAGE, transferred 
proteins to a PVDF membrane and carried out protein blot analysis with an antibody to 
GST. 
CSK FYN inhibition assays. 
We transfected HeLa cells with plasmids driving expression of wild-type (pcDNA3.1–
	

FYN) and activating mutant FYN (pcDNA3.1–FYN Leu174Arg, pcDNA3.1–FYN 
Arg176Cys and pcDNA3.1–FYN Tyr531His) alone or with a vector driving expression of 
CSK (CSK-pcDNA3.1) at 1:1 and 1:3 ratios and analyzed the levels of FYN activation 
and FYN and CSK expression via protein blot analysis. 
Dasatinib FYN inhibition assays. 
We transfected HEK293T cells with vectors driving the expression of activated mutant 
FYN proteins (pcDNA3.1–FYN Leu174Arg, pcDNA3.1–FYN Arg176Cys and pcDNA3.1–
FYN Tyr531His). After 24 h, cell cultures were treated with increasing concentrations of 
dasatinib (Selleck Chemicals) for 6 h and were analyzed for FYN phosphorylation and 
expression by protein blot analysis. Similarly, transformed Rat1A cells expressing the 
FYN Tyr531His mutant or a double FYN Thr342Ile/Tyr531His mutant were treated with 
vehicle alone or with dasatinib (1 M) for 6 h and analyzed for FYN phosphorylation and 
expression by protein blot analysis. 
Cell proliferation assays. 
We analyzed relative cell growth at 72 h in vehicle-treated and dasatinib-treated (1 M) 
Rat1A transformed cells expressing either the FYN Tyr531His mutant or a FYN 
Thr342Ile/Tyr531His double mutant. Cell growth was determined in triplicate by 
measurement of metabolic reduction of the tetrazolium salt MTT using Cell Proliferation 
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